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Preeclampsia is a clinical syndrome affecting only pregnant women and is defined as new 
onset of hypertension and proteinuria after 20 weeks of gestation. Approximately, 2-7 % of all 
pregnant women in the developed world are affected by this condition and it is a major cause 
of maternal and fetal morbidity and mortality. Despite intensive research the pathophysiology 
of preeclampsia is not fully understood.   
 
Laeverin is a gene encoding for a membrane bound-cell surface metallopeptidase (MMP) 
expressed on extravillous trophoblast (EVT). The EVT cells are responsible for remodelling 
of maternal spiral arteries during placental development. It has been suggested that laeverin 
may be involved in the regulation of invasive EVTs during early human placentation. Gene 
expression studies using microarrays have documented that laeverin is ten fold-up regulated 
in preeclamptic placentas compared to normal placentas, indicating its possible  involvement 
in the pathophysiology of preeclampsia. Immune fluorescence studies of placental tissue 
sections from normal and preeclamptic patients documented that in preeclamptic placentas 
laeverin is expressed in cytoplasma, while in normal placentas it is expressed in the cell 
membrane. The laeverin gene was therefore sequenced to detect possible mutations which 
could be linked to the pathogenesis of preeclampsia.  
 
We found one variant documented exclusively in blood from one preeclamptic patient in exon 
7 position g.1459G˃A which replaces one Glutamic acid with Lysine. Since it was not present 
in any normal controls this may be a pathogenic mutation and should be further investigated. 
 
Several studies have indicated a possible fetal contribution to development of preeclampsia. 
By performing array comparative genomic hybridization (aCGH) analysis which detects 
deletions and duplications in the whole genome in one single test, we investigated if umbilical 
cord blood from fetuses of preeclamptic women contained mutations which may be associated 
with preeclampsia.  These results were compared to the results from an aCGH analysis on 
maternal blood.  
 
Numerous copy number variations were detected and some of them contained genes involved 
in vesicle transportation within the Golgi apparatus, protein folding, protein trafficking, 
 
 
immunological processes, maintenance of cell membranes, pregnancy-specific glycoproteins, 
complement system, tissue invasion and angiogenesis. These genes should be further 
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Genetics involves the study of inheritance in organisms. The first genetic study was published 
by Gregor Mendel in 1865. He crossed strains of garden peas with different traits and studied 
their offspring`s phenotype distribution pattern. The distribution of the traits followed a 
certain inheritance pattern, now known as the Laws of Mendel. At the beginning of the 19th 
century evidences was found indicating that deoxyribonucleic acid (DNA) is the genetic 
material in organisms, and that genes are the basic elements of inheritance (1).  In humans the 
genetic material is distributed on two genomes, the nuclear and the mitochondrial.  
 
The DNA is made up of long linear stretches of nucleotides. A nucleotide consists of a 
phosphate group, a nitrogen base and a sugar called deoxyribose. There are four different 
types of nucleotides; Guanine, Cytosine, Adenine and Thymine. The only difference between 
these four nucleotides is the structure of the nitrogen base. The four nucleotides are connected 
to each other by sugar-phosphate bonds which connects the hydroxyl group on the 3`carbon 
with the phosphate group on the 5`carbon of another nucleotide, making a long linear chain of 
DNA. Human DNA is double stranded, consisting of two linear chains of DNA paired 
together, forming a double helix with hydrogen bonds between the nitrogen bases in the 
nucleotides; Guanine pairs with Cytosine, and Thymine with Adenine (2).  
 
The DNA helixes are packed with a type of proteins called histones, and two DNA helixes 
surrounded by histones constitute a chromosome. There are five different types of histones, 
H1, H2A, H2B, H3, and H4 (2). Positively charged amino acids in the histones form 
electrostatic interactions with negatively charged phosphate groups in the DNA molecules and 
are essential for the molecule`s structure. The human genome consists of twenty-three pairs of 
chromosomes. The two chromosomes which form a chromosome pair are called homologous 
chromosomes. Since humans have two sets of each chromosome, our genome is said to be 
diploid. Twenty-three chromosomes are inherited from an individual’s mother and twenty-
three from the father. Chromosomes 1-22 are called autosomes and are similar for both sexes. 
X and Y are the sex determining chromosomes. Men have one X- chromosome and one Y- 
chromosome, whereas women have two X- chromosomes. The different chromosomes vary in 
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size and amount of genes, but they all consist of one p arm (petite) and one q arm (queue), 
separated by a centromere (2).   
 
DNA is the basis for production of proteins, and is divided into coding sequences, repetitive 
elements and none- coding elements. The coding part of the double helix is made up of genes 
that code for amino acids and is essential in protein production.  The genes are divided into 
exons and introns. Exons are nucleotide sequences which code for amino acids. Three 
nucleotides together form one codon which encodes for one specific amino acid. When genes 
are expressed, RNA polymerase synthesizes a complementary strand from a template strand 
in the gene in a process called transcription and forms pre-mRNA. Pre-mRNA consists of 
both introns and exons and is immature. Mature mRNA is formed when introns are cut out of 
the pre-mRNA. The mature mRNA is translated into polypeptide chains in a translation 
process where the amino acids encoded for are bound together by peptide bonds and forms 
long linear polypeptide chains which are further processed into proteins (2).  
 
1.2 Mutations 
A mutation is a permanent alteration in the DNA sequence and may be pathogenic or benign 
depending on the mutation`s genome position and type of mutation. Large mutations may 
involve whole chromosomes or parts of chromosomes resulting in a decreased or increased 
production of several proteins and may cause severe disease.  However, pathogenic mutations 
could also originate from one single mutated nucleotide. Most of the pathogenic mutations are 
detected in exons, an exception from this is mutations localised in splice sites where introns 
are cut out of mRNA. There are several types of mutations and they are grouped into gene 
mutations, chromosome mutations and genome mutations (3). 
 
1.2.1 Gene mutation 
A gene mutation involves substitution, deletion or addition of one or a few base pairs (bp) in a 
gene and may result in alterations of codons. Mutations causing replacement of one codon 
with another coding for the same amino acid has no effect and are called silent mutations.  If 
the codon is replaced by a codon coding for a different amino acid the mutation is a missense 
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mutation. Gene mutations could also alter the reading frame and form new codons which 
change the amino acid composite in the protein. This type of mutation is called frameshift 
mutation. In most cases the outcome of an altered reading frame is a truncated (non- 
functional) protein. Gene mutations may also result in the formation of a premature stop 
codon and lead to production of a truncated protein. This type of mutation is called a nonsense 
mutation (3). 
 
1.2.2 Genome mutation 
A genome mutation is a mutation altering the number of chromosomes. The human genome 
normally constitutes of forty six chromosomes. Aberrations in the number of chromosomes 
could involve the whole chromosome set, for instance sixty nine chromosomes instead of 
forty six (triploid), or the number of individual chromosomes.  Some of these syndromes are 
viable eg.  Klinefelter syndrome (47, XXY), Triple X syndrome, (47, XXX), Turner 
syndrome (45, X), and Down syndrome (trisomy 21). Edward syndrome (trisomy 18) and 
Patau syndrome (trisomy 13) are lethal genetic syndromes and individuals with these 
syndromes die in utero or within a short period after birth (3). 
 
1.2.3 Chromosome mutation 
A chromosome mutation is a mutation affecting a part of the chromosome and is large enough 
to be detected using a light microscope. These are classified as duplications, deletions, 
inversions, and translocations. Deletions involve loss of a chromosome segment while 
duplications results in gains of an extra part of a chromosome  (3). In inversions one segment 
is cut out of a chromosome due to two chromosomal breaks on the same chromosome and is 
inverted before it is re-inserted between the two breaks (3).  A translocation is a mutation 
where two chromosomes exchange segments, and usually involves non-homologous 
chromosomes (3). Several syndromes are caused by chromosome mutations, for example 





1.3 Inheritance patterns 
A genetic disease is caused by mutations in the DNA and may be inherited or acquired. 
Mutations in germ cells are inherited and are passed through generations, while mutations in 
somatic cells arise de novo and are not inherited. Genetic diseases caused by a mutation in one 
single gene are called single gene disorders. Some genetic diseases are dependent on gene-
gene interactions and gene-environmental interactions to cause diseases  and are complex 
genetic disorders (4). Many different inheritance patterns exist and some of these are 
presented below.  
 
1.3.1 Autosomal dominant inheritance 
An autosomal dominant disease originates from a mutation in one single gene on an 
autosome, and one mutated copy is enough to cause disease (3). Each offspring of a parent 
who has the mutation has a 50 % chance for inheriting the mutated gene and developing the 
disease. In most cases the disease is represented in every generation, and every affected 
individual has an affected parent (3).  
 
1.3.2 Autosomal recessive inheritance 
An autosomal recessive disorder is caused by a mutation in one single gene on both of the 
autosomes.  Two copies of the mutated gene are necessary for  manifestation of the disorder, 
and therefore both parents of an affected individual are carriers of the disease (3). In most 
cases the parents are unaffected by the disease and may not be aware of their carrier status. 
Each offspring has a 25 % chance for inheriting the disease (3). 
 
1.3.3 X linked – dominant inheritance 
An X-linked dominant disease is developed from a mutation in one gene on the X 
chromosome. Both genders are affected, but characteristic for this inheritance pattern is that 
the boys are more severely affected than the girls (3). Girls have two copies of the X- 
chromosome and in each cell only one of them is expressed. In some cells the mutated X-
chromosome is inactivated and in others the normal, they therefore produce some of the 
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proteins encoded for by the normal X. Boys have only one copy of the X- chromosome and if 
they inherit a mutated X, it is expressed in all cells causing more severe disease. Sons of a 
man with an X-linked mutation do not inherit the mutated gene while all his daughters do. 
Both sons and daughters of an affected female have a 50% risk for inheriting the mutated X 
(3). 
 
1.3.4 X- linked recessive inheritance 
In X- linked recessive disorders boys are more often affected than girls. Boys have only one 
copy of the gene and will therefore develop disease if they inherit the mutated copy from their 
mother. Girls are only affected if they inherit one mutated copy from each parent. In cases 
where the father has the mutated gene, his sons are unaffected and his daughters are carriers. 
If the mother carries the mutated gene her sons have a 50 % risk of being affected and her 
daughters have a 50 % risk of being carriers (3). 
 
1.4 Detection of mutations 
During the last decades there has been a significant expansion in the number of methods used 
in medical genetics to detect mutations. 
 
Banding techniques 
Cytogenetic is the study of chromosomes. Chromosomal banding techniques developed in the 
1970s  were the first methods for detection of chromosomal aberrations (5). There are several 
types of banding techniques. Common for them is the colouring of chromosomes in different 
patterns to detect aberrations (3). The methods identify chromosomes, detect aneuploidy and 
large aberrations such as deletions, duplications and translocations (5). Chromosomal banding 
techniques can detect aberrations larger than 3-5 megabases (Mb) (6). 
 
One banding technique is G (Giemsa)-banding where the chromosomes are stained into dark 
and light bands which divide the chromosome into different regions (figure 1) (3). The dark 
and light bands are labelled with different letters and numbers. Bands on the long (q) arm are 
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labelled q followed by a number indicating their chromosomal position. On the short (p) arm 
the bands are labelled p followed by their number position. The numbers following the letter p 
or q are counted outwards from the centromere, meaning that both ends of the chromosome 
have the highest number and the centromere the lowest (7). The specific chromosome bands 
are used to pinpoint the localisation of the mutation in the genome (7). 
 
Figur 1:. Illustration of chromosome pair 5, after G-banding. Staining with Giemsa creates a pattern of light and 
dark bands which divides the chromosome into different regions and pinpoints the chromosome location for 
detected mutations. The centromere  represents the thinnest area on the chromosomes. The p arm is positioned 
above the centromere and the q arm below.   The picture is modified from  a karyogram  made by Mona Nystad, 
Divison of Child and Adolescent Health, Department of Medical Genetics, University Hospital of North 
Norway, Tromsø, Norway. 
 
The whole set of one individual`s chromosomes is referred to as a karyotype.  Normal males 
have 46, XY as karyotype, while normal females have 46, XX. Chromosomes are often 
displayed in a picture with pairs of homologous chromosomes beside each other, called a 
karyogram (figure 2). Each chromosome pair has distinct features that make it possible to 




Figure 2: This karyogram displays the karyotype of a normal male. The homologous chromosomes are grouped 
together and positioned based on their chromosome number. All chromosomes have distinct features which 
distinguish them from each other. The karyogram was made by Mona Nystad, Divison of Child and Adolescent 
Health, Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway. 
 
 
Owing to the fact that chromosomal banding techniques only detect aberrations larger than 3-
5 Mb, there was a need for development of methods detecting smaller mutations. 
Fluorescence in situ hybridization (FISH) analysis and multiplex-ligation dependent probe 
amplification (MLPA) analysis are examples of higher resolution methods. These methods are 
considered to be a form of bridge between cytogenetics and molecular genetics. FISH and 
MLPA-methods detect microdeletions and microduplications, which are mutations of less 
than 2 Mb (5, 8). Their limitation is, however, that they require knowledge of the disease 
causing mutation`s genome position (8, 9).  Furthermore, since only small parts of the genome 
are investigated in one test, it can be very time-consuming to diagnose patients with these 
methods. 
 
During the last decade several methods for the detection of mutations in the whole genome in 
one single test have been developed. Whole genome sequencing, comparative genomic 
hybridization (CGH), array comparative genomic hybridization (aCGH) and single nucleotide 
polymorphism (SNP) arrays are all methods which screen the whole genome for mutations in 
one single test. Implementation of these methods has resulted in detection of many previously 
8 
 
unknown pathogenic mutations. Disadvantages with the whole genome approach are new 
ethical problems following the huge amount of information provided by these methods, and 
troubles with interpretation of the clinical importance of all the detected mutations. 
 
1.5 Copy number variation  
Many regions in the human genome have variations in number of copies (CNVs) of a specific 
sequence as a result of deletions or duplications of this sequence. Copy number variations 
could be inherited or arise de novo (10). According to Choy et al, a CNV is defined as 
stretches of DNA larger than 1000 base pairs which normally are found only once on each 
chromosome in one individual, but  can be duplicated or triplicated in some individuals  
resulting in a variation in number of copies between different individuals (10). About 12 % of 
the human genome consists of CNVs, and over 41 % of these overlap with known genes (10). 
 
CNVs of specific regions on human chromosomes are often involved in the development of 
human diseases (8, 11) and are increasingly found to be associated with risk for development 
of several diseases, such as neurological disorders, several types of cancer, autoimmune 
disorders and several syndromes (table 1) (10). Standard chromosome analysis, CGH, FISH, 
MLPA, Bacterial artificial chromosomes (BAC) arrays, Southern blot and quantitative PCR 
(qPCR) are all analyses used to detect CNVs (8, 11). CGH has a resolution of 5-10 Mb and is 
not able to detect smaller CNVs than 5Mb (12). As a consequence array comparative genomic 














Table 1: CNVs associated with human diseases, modified from reference (10). 
Disorder CNV Gene Effect Risk associated 
Infectious Disease     
HIV-1/AIDS susceptibility Common CCL3L1 Dosage Low CNV 
Autoimmune Disorder     
Systemic lupus erythematosis (SLE) Common FCGR38 Dosage Low CNV 
Psoriasis Common DEFB Dosage High CNV 
Crohn`s Disease Common HBD-2 Dosage Low CNV 
Neurological Disorders     
Autism Spectrum Disorders unknown Multiple Unknown De novo CNVs; 
Multiple CNVs 
Parkinson`s disease Rare SA/CA Dosage Duplication/Triplication 
Bipolar disorder Rare GSKSb Dosage Deletions and duplications 
Schizoprenia Rare Multiple Positional Deletions and duplications; 
de novo CNVs 
Cancers     
Breast cancer Rare MTTUS1  
(exon 4) 
Positional Exon deletion  
(decrease risk) 
Prostate cancer Common UGT2B17 Positional Gene deletion 
Neuroblastoma Common NBPF23 Dosage Deletions and duplications 
 
 
1.6 Array comparative genomic hybridization 
Array comparative genomic hybridization is a method for detection of CNVs and is based on 
CGH developed by Kallinomi et al in 1992 (14).  aCGH identifies submicroscopic CNVs in 
the whole genome at high resolution in one single test (12). The aim of performing  aCGH is 
to detect pathogenic chromosomal aberrations or CNVs (12).  
 
 aCGH is based on hybridization of differently labelled DNA from a patient and a normal 
control added to a microscope slide containing probes. The amount of hybridized DNA is 
measured by fluorescent signals detected by a scanner. These signals are then converted into 






For the detection of CNVs in the patient’s genome the patient`s DNA is compared to DNA 
from a normal control. This is accomplished by labelling an equal amount of genomic DNA 
from the patient (green) and normal control (red) with different fluorescent colours. The 
differently labelled DNA are mixed together and added to probes on a microscope slide (10), 
where they compete for hybridization to the probes (14). After hybridization the fluorescent 
signals are detected by a laser scanner (14). If the patient`s DNA lacks CNVs, there will be an 
equal amount of both fluorescent signals and the colour on the array is yellow. If the patient`s 
DNA contains duplications, more of the patient`s DNA than the normal control will hybridize 
to the probes, creating a higher intensity of the green fluorescent signal and this area on the 
array will be green. In cases where patient`s DNA contains deletions, less of the patient`s 
DNA will hybridize to the probes compared to the normal control, producing a stronger red 
fluorescent signal. The colour of this location on the array will be red (14). A computer 
software is used to convert the fluorescent signals into a fluorescent ratio profile (figure 3), 
where duplicated and deleted regions are presented. The Y axis presents the log2 ratio which 
is a measure of the size of the CNV (number of copies) while the X axis documents its 
chromosomal position. Genome positions with no detected CNVs are contained at the zero 
line for the log2 ratio. Duplications are localized above the zero line and deletions below.  
Mutations with large copy number variations are located further from the zero line than small 
mutations. Duplications of one copy number result in a log2ratio around 0.5, while deletions 






Figure 3: Illustration of the array CGH principle. The patient`s DNA is labelled with green fluorescence and the 
normal control with red fluorescence. The coloured DNAs are mixed and hybridized to probes on the array. 
After hybridization the array is scanned and the light intensities are analyzed using specialized software. Areas in 
the genome which are deleted in the patient`s DNA are represented as red circles, while duplicated areas are 
represented by green circles. The software converts the fluorescent signals into a fluorescence ratio profile where 
the log2 ratio on the Y axis indicates the size of the CNV.  The X axis shows the detected CNVs position in the 
genome. 
 
The number of CNVs detected by aCGH depends on the resolution and type of array. The 
resolution is dependent on the number of BAC or oligonucleotides on the array. The higher 
the number of probes better the resolution (5). Targeted arrays focus on known deletion and 
duplication in the genome (12, 15) ,while tiling arrays screen the whole genome for CNVs 
(12, 16).  
 
Several studies have indicated that when aCGH is performed after obtaining a normal 
karyotype analysis, the  diagnostic yield is increased by 8-17% (12). However aCGH only 
detects copy number variations, and therefore polyploidies, balanced translocations and 
inversions are not detected with this method (17). One disadvantage of aCGH is that CNVs of 
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unknown clinical significance are often detected when the whole genome is screened. These 
findings may be difficult to interpret and therefore guidelines for evaluation of the aCGH 
results have been developed (figure 4) (12). Detection of known pathogenic CNVs should 
always be verified by another independent method. When CNVs of unknown clinical 
significance are detected the Database of Genomic Variants (DGV) should be screened. The 
DGV is a database containing information on known structural variants in healthy individuals.  
If the detected CNV is not documented  in DGV or found in healthy parents of the tested 
individual, it is considered to be a potential pathogenic mutation and should be verified by 
another method (12). FISH and qPCR are often used to verify aCGH results (12). If the 
detected CNV is present in the DGV or found in healthy parents of the tested individual it is 
considered to be benign.  
 





















Figure 4: Flowchart representing the guidelines for the interpretation of aCGH results. Modified from reference 
(12). 
 
CNVs are increasingly linked to several diseases and it is possible that CNVs in the fetal 





1.7 The Placenta 
The placenta is a temporarily organ which develops and functions during pregnancy. Its 
function is to support normal growth and development of the fetus (figure 5A) (18).  
 
1.7.1 Development and morphology 
The placenta (chorion) develops from a fertilized zygote which undergoes several mitotic cell 
divisions and differentiates into different cell types (19). After a certain number of mitotic cell 
divisions it becomes a blastocyst and implants into the endometrium in the uterine wall. The 
formation of the placenta starts with a reaction called the decidual reaction in the uterine wall. 
Here the stroma cells adjacent to the implanted blastocyst differentiate into metabolically 
active decidual cells (19). After implantation the trophoblast cells proliferate and differentiate 
into two pathways, the extravillous and villus pathway (18). The trophoblasts in the villus 
pathway are responsible for the creation of the fetal part of the placenta, the villus tree 
formation (figure 5B).  Extravillous trophoblasts (EVT)  connects the placenta to the maternal 
circulatory system by remodelling the maternal spiral arteries and develops the utero- 
placental circulatory system (18, 19). The spiral arteries are remodelled by invasive EVT cells 
that invade and replace the muscular layer of these vessels and makes the spiral arteries 
unresponsive to maternal vasomotor control (18, 20). 
 
The villus tree consists of a large amount of villi (figure 5C). The villus consist of a fetal 
blood vessel surrounded by mesenchymal tissue, and an inner and outer layer of trophoblasts 
(21). The mononucleated cytotrophoblasts constitute the inner layer (illustrated in pink in 
figure 5C) of trophoblasts and are formed by invading cytotrophoblasts in the uterine wall. 
Non-migratory villous cytotrophoblasts fuses together and forms a growing layer of 
multinucleated syncytiotrophoblasts  (illustrated in blue on figure 5C) which constitutes the 
outer layer and gradually covers the whole surface of the placenta (18, 21).  
 
The umbilical cord connects the placenta to the fetus. It consists of two arteries carrying 
deoxygenated blood and waste substances from the fetal circulation to the placental villi and 
into the maternal circulation. A single umbilical vein carries oxygenated blood from the 
placenta to the fetus. (figure 5B) (18). The villi in the villus tree project into the intervillous 
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space which separates the maternal side of the placenta from the fetal side (figure 5B). 
Exchange of nutrients gas and waste products happens in the intervillous space. Here spiral 
arteries soak the intervillous space with maternal blood and substances from maternal blood 
enter fetal blood by diffusion through the villi (18). 
 
Figur 5: A: Illustration of a placenta with the umbilical cord. B: The villus tree formation on the fetal side of the 
placenta. The intervillous space surrounds the villus tree which is soaked in maternal blood. The villi in the 
villus tree are illustrated in red and blue circles surrounded by a white space which represents the placental 
membrane that separates fetal blood from maternal blood. C: The villi structure with different cells. 
Cytotrophoblasts (pink cell layer) syncytiotrophoblasts (blue) and capillaries (red). 
 
In the first trimester of pregnancy many spiral arteries are totally occluded as a result of 
trophoblast plugging causing a reduced blood flow to the placenta. The fetus receives a 
reduced amount of oxygen and is protected from excessive amounts of oxygen which could 
be damaging during critical stages in early development (21, 22). Between 8 and 12 weeks of 
gestation there is a significant increase in blood flow and the occlusions caused by trophoblast 






1.7.2 Function of the placenta 
The placenta has several functions  and its main functions can be categorized into transport, 
metabolism, defence and endocrine function (18). 
 
The placenta supplies the fetus with nutrients (oxygen, water, lipids, carbohydrates, amino 
acids, vitamins and minerals) from the maternal blood and eliminates waste substances 
(carbon dioxide, urea etc) from the fetal blood (18). It is also able to metabolize substances 
and release metabolic products into the maternal and fetal circulations (18). Supply of 
antibodies from the maternal blood circulation to the fetus helps to protect it from infections 
caused by virus and bacteria. Hormones affecting pregnancy (metabolism and growth) are 
produced and secreted from the placenta to the fetal and maternal circulations (18). 
 
1.8 Preeclampsia 
Preeclampsia is a clinical syndrome affecting only pregnant women and  is defined as a new 
onset of hypertension and proteinuria in pregnant women after 20 weeks of gestation (23). In 
addition to hypertension and proteinuria systemic endothelial cell activation and  
inflammatory response are characteristic (21). Preeclampsia complicates 2-7 % of all 
pregnancies in healthy nulliparous women in developed countries and the incidence might be 
even higher in the developing countries (24). For women with previous pregnancies affected 
by preeclampsia the prevalence rate is approximately 18% and 14% for twin pregnancies (24).  
 
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality and can only 
develop in the presence of a placenta. The only cure for preeclampsia is therefore removal of 
the placenta by delivering the fetus (21).  There are two types of preeclampsia, early onset and 
late onset.  Early onset is the most severe and is associated with abnormal villus and vascular 
structure. Onset is before 34 weeks of gestation and the fetus is often affected by growth 
restriction (21). Furthermore the fetus can be affected by nutritional and respiratory 
insufficiency, asphyxia and death (25). Late onset is the most common form of preeclampsia 
and constitutes approximately 80% of all cases around the world. It usually has normal 
placental morphology and is not associated with fetal growth restriction (21). Women affected 
by severe preeclampsia may develop haemolysis, elevated liver enzymes, and low platelet 
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count syndrome (HELLP). Up to 20%  of women with severe preeclampsia develop HELLP 
syndrome (26).   
 
The pathophysiology of preeclampsia is still not fully understood, but it involves a 
complicated network of maternal and fetal interacting factors (21).  
 
1.8.1 Development of preeclampsia 
Development of preeclampsia is categorised into two stages, preclinical and clinical. The 
preclinical stage is before the maternal symptoms start to develop, and the clinical is after 
(25).  Poor placentation  is typical for the preclinical stage and is caused by an aberrant 
development of the early placenta and maternal blood supply (25). Defects in trophoblast 
differentiation may cause a reduced amount of extravillous trophoblasts, resulting in a 
reduction of the number of remodelled arteries and their depth of remodelling (21). 
Inadequate remodelling leads to reduced blood flow to the placenta in second and third 
trimester, inducing  a gradually more and more hypoxic placenta (25, 27). The hypoxic 
placenta releases factors into the maternal circulation which are believed to induce the 
maternal symptoms like hypertension, proteinuria, clotting and liver dysfunction (25, 28, 29). 
These factors originate from an inflammatory response with endothelial dysfunction as a main 
component (25, 28).  
 
Involvement of the immune system in the development of preeclampsia has been shown by 
several research groups. Decidual natural killer cells (dNK) and decidual macrophages are 
essential cell types implicated in immunological theories. The dNK cells infiltrate the 
decidualized uterus before implantation and remain in large quantities throughout the first 
trimester. Evidence suggests that they play a direct role in the remodelling of spiral arteries 
and tropohoblast invasion. There is however limited data on how dNK cells are involved in 
preeclampsia and research performed in this field provides conflicting results (21). One theory 
presented is that poor placentation and preeclampsia is less common in individuals where 
trophoblast stimulates dNK cells strongly by binding to their receptors (25). Decidual 
macrophages are believed to have the ability to disrupt vascular smooth muscles in spiral 
arteries before invasion of extravillous trophoblast, and may therefore influence the 
remodelling of spiral arteries and development of  preeclampsia (21).  
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1.9 Genetics of preeclampsia 
Despite extensive research and a large number of published studies the aetiology of 
preeclampsia remains unknown. Studies have revealed that there is a clear familial 
predisposition and a high recurrence risk for severe preeclampsia in pregnant women with 
earlier pregnancies affected by preeclampsia. Both of these factors are indications for a 
genetic contribution (23, 29-31).  However, so far no specific genes have been identified that 
cause preeclampsia. Preeclampsia is in most cases considered to be a complex genetic 
disorder and conflicting results seems to be characteristic for the genetic studies performed 
(30).  
 
Many factors contribute to the difficulties in establishing the aetiology of preeclampsia. 
Diagnosis of preeclampsia is often based on different thresholds for blood pressure and 
proteinuria. Several hypertensive disorders linked to pregnancies can be mistaken for being 
preeclampsia because of similar symptoms (32). Severity and involvements of different 
organs are often also highly variable between individuals, and could result from different 
molecular mechanisms (30). Early and late onset preeclampsia have different clinical 
characteristics and many studies lack distinction between these two types, that potentially 
could originate from different molecular mechanisms.  Another problem is the difficulty in 
comparing and interpreting the findings of studies performed on placental samples obtained at 
different stages of development. Gene expression profiles from placentas differ between 
different gestational ages and are a source of conflicting results when they are compared to 
each other. Both the paternal and maternal genotypes may be responsible for development of 
preeclampsia (30, 33). Furthermore, fetal and maternal genomes may have genes that by 
themselves or together may be responsible for preeclampsia (32, 33). The paternal genotype 
should therefore also be investigated. Genetic variation between populations are also reasons 
for contradicting results since different molecular mechanisms may be present in different 
ethnic populations (33). The majority of studies have focused on maternal genes and therefore 
the Genetics of Pre-eclampsia Consortium has highlighted the need for studies performed on 






1.9.1 Inheritance pattern 
 
Twin studies 
Twin studies have been performed to investigate the relationship between genetics and 
environmental factors in preeclampsia (33). These studies show conflicting results (29). The 
first study reported a low concordance of development of preeclampsia between monozygotic 
twins indicating a low heritability by maternal genes.  A more recent study performed based 
on material from the large Swedish Twin, medical Birth and multigeneration register reported  
the heritability of preeclampsia to be around 55 % with contribution from both maternal and 
fetal genes(33). Another twin study performed in Sweden reported the preeclampsia 
penetrance between twin sisters to be less than 50 %, representing a diversity in the 
inheritance pattern (33). 
 
Paternal contribution 
There are several indications for paternal contribution in the development of preeclampsia. 
Research documents that women with subsequent pregnancies with the same partner have a 
lower risk for developing preeclampsia, while women with subsequent pregnancies fathered 
by different partners have a higher risk (21, 31). Long term exposure to paternal antigens may 
induce a form for immunological memory (21). For women with preeclampsia in their first 
pregnancy, a change of partner may lower the risk for preeclampsia since the new partner 
could have more compatible HLA C molecules on their trophoblast cells and receptors (21). A 
higher rate of preeclampsia is also documented in pregnant women with a partner who 
himself was born of a woman with preeclampsia (27, 29, 33, 34). Another evidence for 
paternal contribution is that men who earlier have fathered pregnancies with preeclampsia, 
have a higher risk of fathering a new pregnancy with preeclampsia with a new partner (29). 
 
Complex genetic disorder 
Based on previous research, preeclampsia is considered to be a complex genetic disorder in 
the general population with some exceptions following the Mendelian inheritance pattern (29, 
33). A complex genetic disorder is an inherited disease which is not caused by a single gene 
and that deviates from the Mendelian inheritance pattern (4). In such cases relatives who share 
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the same genotype may have different phenotypes depending on gene-gene interactions and 
gene-environmental interactions (4). Since most of the preeclampsia cases are considered to 
have a complex genetic cause, it is likely that no single gene or variant will account for all the 
occurrences of preeclampsia (33).   
 
1.9.2 Genetic methods applied to study preeclampsia 
Research studies on preeclampsia are performed on different population groups and with 
varying methods, such as the candidate gene approach, genome wide linkage studies, 
imprinting studies, and expression profiles studies (34). 
 
Candidate gene approach 
The candidate gene approach is a widely used method in preeclampsia studies and involves 
selection of one single gene for investigation based on already known information (33). Until 
now more than 70 single genes categorized into different groups based on  pathological 
mechanisms such as oxidative stress, lipid metabolism, thrombophilia immunogenetics, and 
endothelial injury have been investigated (33). All these studies have provided contradicting 
results, and no genes have so far been universally accepted as the cause of preeclampsia (33). 
A selection of the most predominant functional candidate genes are presented in table 2. 
 
Table 2:  Presentation of the most predominant functional candidate genes. Modified from reference (33). 
Pathophysiological 
mechanism group 
Gene name Gene symbol 
Trombophilia Factor V Leiden 
Methylenetetrahydrofolate 
Protrombin 
Plasminogen activator factor-1 






Endothelial function Endothelial nitric oxide synthase 3 
Vascular endothelial growth factor receptor 1 




Vasoactive proteins Angiotensinogen 
Angiotensin converting enzyme 
AGT 
ACE 
Oxidative stress and lipid 
metabolism 
Apolipoprotein E 














Genome- wide linkage screens 
Genome-wide linkage screens (GWLS) is a method where linkage between genetic markers 
with known position distributed throughout the whole genome are investigated. Some linkage 
studies have been performed on preeclampsia, where samples from preeclamptic women and 
their relatives were compared to each other to find possible linkage (33).  One disadvantage 
with this approach is that only relatively large areas which can contain hundreds of genes are 
identified (33). If potential linkage is found, further analysis needs to be performed to find 
possible candidate genes in the linkage region. 
 
 Arngrimsson et al (1999) found a maternal susceptibility locus for preeclampsia on 
chromosome 2p13 (29, 33, 35) with consistent results found by an Australia/ New Zeland 
research group (table 3) (29, 30, 36, 37). Extended work  was performed to reveal associations 
between the potential candidate genes in the 2q22-23 locus (33). Activin A receptor type ΙΙa 
(ACVR2A) was identified as a strong candidate gene, but different research groups published 
contradicting results (33).  GWLS studies performed in Netherland and Finland found other 
susceptibility locus (table 3) (37, 38). The Finish research group investigated the ROCK2 gene 
in the 2p25 locus further, but with disappointing results. No association with preeclampsia 
was documented (33). 
 
Table 3: Outline of performed GWLS studies in the field of preeclampsia, modified from reference (33) 
Country Number of  families  Chromosome loci 
Iceland 
 
124 (343 women) 2p13 
Australia/New Zealand 34 (366 women) 2q23 
11q23 
 
The Netherlands  
 
38 (332 women) 10q22 
22q12 






Many genes are located in conserved clusters where only one allele is expressed, either the 
maternal or paternal allele. This condition is called genetic imprinting. Indications for 
involvement of genetic imprinting with preferential expression of the maternal allele in 
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development of preeclampsia are documented (29) . Several studies have been performed on 
one gene found within the locus 10q22.1 (table 4). This gene encodes for the STOX1 
transcription factor which is believed to be involved in the transformation of invasive 
trophoblasts into non invasive. The data from these studies are contradicting, and further 
studies are necessary to elucidate its role in preeclampsia (33). 
 
Table 4: Studies performed on one gene encoding the STOX1 transcription factor (39-42). 
Research group and 
year 
 Imprinted locus Potential genes Conclusion 
Oudejans et al 
2004 
10q22.1  Downregulated expression in 
hydratiform molar placentas (only 
paternal contribution) 
Djik et al 
2005 
10q22.1 STOX1 Found identical missense mutations in 
STOX1 between affected sisters 
Iglesias et al 
2007 
10q22 STOX1 Detected biallelic expression of STOX1 
in both normal and preeclamptic 




10q22 STOX1 Overproduction of STOX1 reproduces 
transcriptional effects of preeclampsia. 
 
Another gene examined for possible imprinting status is the H19 gene which is involved in 
regulation of growth and development of the embryo, and differentiation of cytotrophoblast 
cells (43).  L. Yu et al (2009) documented that biallelic expression of H19 existed in some 
cases in early stages of normal pregnancy and changed to monogenic expression around 10 
weeks, while preeclamptic placentas had biallelic expression in third trimester. (33, 43). 
Bourque et al (2010) found no reduced methylation at ICR1 which is an imprinting region 
regulating the H19 gene indicating that there is no biallelic expression in placentas from 
women with preeclampsia and contradicted Yu`s study (44). 
 
Microarrays and gene expression  
Gene expression varies between different cell types and cell stages (4). Several gene 
expression studies have compared profiles in preeclamptic placentas with normal placentas 
with conflicting results (4). Sitras et al compared his results from a gene expression study on 
preeclamptic placentas with 16 previously performed microarray studies and found some 
similarities of differentially expressed genes in women with preeclampsia compared to normal 
pregnancies. Leptin, Human chorionic gonadotropin (hCG), Vascular endothelial growth 
factor (VEGF), Insulin- like growth factor 2 (IGF2), Laeverin  and Matrix metalloproteinases 




Several genes found to be either up or down regulated in microarray studies have been further 
investigated by the candidate gene approach to gather more information of the origin of 
preeclampsia.  
 
1.9.3 Genes involved in early versus late preeclampsia 
 Sitras et al (2009) documented differences in gene expressions between early onset and late 
onset preeclampsia in his study. By comparing their gene expression profiles indications for 
involvement of different pathways in early and late onset  of preeclampsia was found (23). 
 
Enquobahrie et al (2011) compared gene expression profiles from early pregnancy peripheral 
blood from preeclamptic patients with gene expression profiles of placental tissue from 
preeclamptic women at delivery. They found gestational age and tissue specific differences in 
pathophysiological processes such as vasculature development  in early preeclampsia versus 
hypoxia response in late preeclampsia (45). Numerous other studies have been performed on 
early and late preeclampsia on both maternal blood and tissue samples from placenta. In these 
studies inconclusive results are reported. A review based on current and earlier gene 
expression studies suggests that early preeclampsia is associated with alterations in 
angiogenesis and immune inflammatory response, while late preeclampsia is associated with 
alterations in response to hypoxia or oxidative stress and subsequent endothelial dysfunction 
(45). 
 
1.10 The Laeverin gene 
Sitras et al (2009) documented that laeverin (LVRN) was 10 fold up- regulated in 
preeclamptic placentas compared to normal controls (23).  Laeverin encodes for a membrane-
bound cell-surface metallopeptidase isolated from chorion lave and is therefore named 
laeverin (46) Matrix metalloproteinases degrade the extracellular matrix and are secreted from 
extravillous trophoblasts. They are considered to regulate EVT invasion in cooperation with 
their inhibitors (47). Fujiwara 2007 reported that the metalloproteinase encoded by laeverin is 
only expressed on EVTs, indicating that it is a specific marker of EVT (47). The 
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metallopeptidase encoded by laeverin have some similarities with the CD13/aminopeptidase 
N. CD13/aminopeptidase is necessary for endothelial cell invasion (48) and controls the 
endothelial cells motility by rearranging the cytoskeleton to create filopodia formation (23). 
Petrovic et al  2007 performed a study were they documented that inhibition of CD13 activity 
during the cell recovery phase followed by depletion of cholesterol or trypsinization 
prevented formation of filodopia and disrupted the distribution of membrane proteins (48).  
 
 Furthermore Maruyama et al documented that the cDNA from laeverin encodes for a protein 
consisting of 990 amino acid residues containing one motif specific for the M1 family of 
aminopeptidases (49). According to this study the protein encoded by laeverin cleaves the N- 
terminal amino acid of many peptides, ex angiotensin ІІІ, kisspeptin-10, and endokinin C (49, 
50) which are substances expressed in large quantities in the placenta. Based on this 
documentation it is suggested that laeverin has an important role in placentation through 
regulation of important peptides in this process (49). Goto et al has recently indicated that 
laeverin is important in maintenance of normal pregnancies in humans (50). 
 
After Sitras et al (2009) documented that laeverin was tenfold up- regulated in preeclamptic 
placentas, Nystad et al performed a immunefluorescence study on placental tissue (un-
published study). Fluorescence marked antibodies directed against the laeverin protein were 
applied to tissue sections of placenta to reveal the localisation of the protein within the cell. In 
normal placenta laeverin was localised to the cell membrane and in preeclamptic placentas 
laeverin was localized to the cytosol. Further electronmicroscopic studies will reveal the 
subcellular localisation of the protein. Based on this information it was suggested that the role 











The aims of this thesis were to: 
Sequence the laeverin gene in blood samples from patients affected by preeclampsia and 
normal controls to investigate if there were any pathogenic mutations. 
 
Sequence the laeverin gene in placental tissue sample from one patient with preeclampsia and 
investigate whether different mutations are present in the placental tissue sample compared to 
the blood sample from the same patient. 
 
Screen the whole fetal genome for pathogenic deletions or duplications using array aCGH 
analyses on umbilical cord blood samples obtained from the newborns of preeclamptic 
women and compare with umbilical cord blood obtained from the newborns of women with 
healthy pregnancies.  
 
Determine the chromosomal location and genes included in the CNVs identified. 
   
















2.0 Material and methods 
 
2.1 Patient samples and normal controls 
2.1.1 Normal controls 
As normal controls ten samples from healthy individuals were used and consisted of EDTA 
blood from four women (K1-K4) and from six men (M1-M6). DNA was extracted both 
manually with QIAamp DNA Blood Mini Kit (50) and with the automatic method. The DNA 
concentration was within the range 16.0 – 42.5 ng/μl.  Based on the DNA concentration and 
the results from NanoDrop quantifications,  M1, M4, M6, K3, and K4 were selected for use in 
gradient PCR while, M6, and K4 were used in  sequencing.   
 
2.1.2 Patient samples used for sequencing 
Eight samples from women with preeclampsia were sequenced for all exons and parts of 
introns in the laeverin gene, while 20 samples from preeclampsia patients were sequenced for 
exon 7 and 10. The sample material consisted of DNA extracted from EDTA blood samples 
from these women.  DNA was extracted automatically with Biorobot EZ1, and had 
concentrations within the range from 43.5– 112.1 ng/μl.  All patients had severe preeclampsia, 
but in addition some had HELLP syndrome and foetuses with intrauterine growth restriction 
(IUGR). Samples from women with only preeclampsia are not presented with sample number. 
All samples from women with preeclampsia are labelled with P after sample number. Samples 
11P, 20P and 21P are from women with preeclampsia and HELLP syndrome. 1P are from a 
woman with preeclampsia, HELLP and IUGR, while 9P is collected from a woman with 
preeclampsia and IUGR.  
 
One sample from placental tissue was sequenced for all exons and parts of intron in the 
laeverin gene. This tissue sample was collected from the placenta right after delivery and 
frozen in liquid nitrogen. DNA extraction was performed by an employee at the Division of 
Child and Adolescent Health, Department of Medical Genetics, University Hospital of North 




2.1.3 Samples from normal pregnancies used for sequencing 
 Three samples from normal pregnancies were sequenced for all exons of the laeverin gene 
and parts of introns, while 18 samples were sequenced for exon 7 and 10. Furthermore 23 
samples were sequenced for only exon 7.  The sample material consisted of DNA extracted 
automatically from EDTA blood samples with Biorobot EZ1. The DNA concentrations were 
in the range 24.0–142.0 ng/μl. Which samples were sequenced for all exons and which were 
sequenced for only exons 7 and 10 were randomly chosen since all had high enough 
concentrations. Some samples were only marked with a sample number while others were 
marked with an N after sample number or NK. N is a symbol for normal pregnancy and NK 
for delivery of the foetuses by caesarean-section. 
 
2.1.4 Patient samples used in aCGH analysis 
Nineteen samples from umbilical cord blood from preeclamptic pregnancies were selected for 
array comparative genomic hybridization based on DNA concentrations and purity after 
NanoDrop quantification. DNA was extracted from EDTA blood samples with Biorobot EZ1, 
and had concentrations in the range from 32.0-104.1 ng/μl.  All samples were from patients 
with severe preeclampsia. In addition some patients had HELLP syndrome and IUGR. 
Samples from women with only preeclampsia are not presented with sample number. Sample 
9P had IUGR in addition to preeclampsia. Sample 20P, 21P and 30P also had HELLP 
syndrome 
 
2.1.5 Normal controls used in aCGH analysis 
Nineteen samples from umbilical cord blood from normal pregnancies were selected for 
aCGH analysis on the same basis as the samples from preeclamptic patients.  The DNA was 
extracted from EDTA blood samples with Biorobot EZ1, and had concentrations in the range 







2.2 Manual DNA extraction with QIAamp DNA blood Mini Kit (50) 
The DNA from blood obtained from normal controls was extracted with the QIAamp DNA 
blood Mini Kit (50). 
 
Principle 
DNA extraction with QIAamp DNA blood Mini Kit (50) was performed by use of QIAamp 
mini spin columns. These columns contain a silica membrane which is essential in the 
extraction process. 
 
The first step in this extraction method is cell lysis, which is performed by addition of 
protease and buffer to the blood samples extracted.  The combination of these two reagents 
destroys the cell membrane and release the DNA from the cells. After cell lysis the solution 
containing the DNA is added to QIAamp mini spin columns.  DNA is negatively charged and 
will bind to the silica membrane in the columns under high salt conditions. Addition of wash 
buffers and several centrifugation steps removes proteins and other cell components which are 
not negatively charged. These components are not able to bind to the columns and are washed 
away during centrifugation. For elution of DNA from the silica membrane sterile water is 
added (51). 
 
 Material and reagents 
 
Table 5: Kit used for DNA extraction 
 
Table 6: Equipment used for DNA extraction 
Equipment Model  Producer 
Pipette Pipet Lite Ranin 
Centrifuge Centrifuge 5415D Eppendorf 
Centrifuge Biofuge 13 Heracus sepatech 
Vortexer VF2 Janke og Kunkel, KA laboratorietechnik 
Water bath DC 100 Grant 
Kits Producer 






Twenty μl of Qiagen protease K was added to 1.5 ml microcentrifugation tubes.  Then 200 μl 
blood and 200 μl buffer Al were added, before vortexing for 15 seconds and incubation at 
56°C for 10 minutes. After incubation the tubes were centrifuged for a short time to remove 
prospective droplets on the inside of the lid.  Two hundred μl of ethanol was added and 
vortexed for 15 seconds before a short centrifugation. The tube contents were transferred to 
QIAamp Mini Spin Columns, placed in 2 ml collection tubes and centrifuged at 6000 X g for 
one minute. After centrifugation the columns were put into new clean 2 ml collection tubes 
and the old ones were discarded. Five hundred μl of buffer AW1 was added to the columns 
and centrifuged at 6000 X g for one minute. Subsequent to centrifugation the columns were 
placed in new collection tubes and the old ones were discarded. Five hundred μl of buffer 
AW2 were added followed by centrifugation at 20 000 X g for three minutes. The 
centrifugation step was repeated two times and the columns were placed in new 2 ml 
collection tubes while the old ones were discarded. Two hundred μl of sterile water was added 
to the columns followed by incubation for 5 minutes at room temperature. Subsequent to 
incubation the columns were centrifuged at 6000 X g for one minute and the contents in the 
collection tubes were transferred to microcentrifugation tubes and stored. 
 
2.3 Automatic DNA extraction from blood samples 
Automatic extraction was performed on all patient samples and samples from normal 
pregnancies with Biorobot EZ1 and Biorobot M48. 
 
Principle 
DNA extraction with Biorobot EZ1 and Biorobot M48 is based on magnetic-particle 
technology.  The magnetic-particles contain silica membranes and binds negatively charged 
DNA.  The first step is cell lysis where cell walls are lysed by addition of guanidine 
hydrochloride.  Guanidine hydrochloride also prepares the DNA molecules for binding to the 
silica membranes by providing a high salt concentration. Bound DNA molecules are separated 
from the lysate by a magnet which draws the magnetic particles to it. Proteins and other cell 
components will remain in the lysate. Additions of two different wash buffers removes the 
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cell lysate and cleanse the DNA molecules on the magnetic-particles. The first wash buffer 
removes guanidine chloride from the solution while the second one is a low salt buffer 
containing ethanol.  Elution of the DNA molecules is performed by addition of Tris-EDTA 
(TE) buffer (52). 
 
Material and reagents 
 
Table 7:  Kits used for DNA extraction. 
Kits Producer 
EZ1 DNA Blood 350 μl  Kit (48) Qiagen 
Sample Prep Plates 42 well, M48 100 Qiagen 
 
Table 8:  Equipment used for DNA extraction. 
Equipment Model Producer 
DNA extractor BioRobot EZ1 Qiagen 
DNA extractor BioRobot M48 Qiagen 
 
Method 
The EDTA blood samples were mixed by inversion and vortexed before 350 µl were 
transferred to new tubes following the extraction kit.  DNA extraction was performed with 
biorobot EZ1 or Biorobot M48 and 200μl was selected as elution volume. 
 
2.3 Quantification of DNA by NanoDrop 2000 
All extracted DNA samples were quantified by NanoDrop2000 
  
Principle 
NanoDrop 2000 is a spectrophotometer which measure DNA/RNA concentrations at the 
A260 ratio and proteins at A280. Sample purity are evaluated by the A260/280 ratio (53). The 
amount of light absorbed by the quantified DNA is measured and computer software 
calculates the concentration of DNA molecules present based on the amount of light 
absorbed. Absorption values are measured at several different wavelengths to evaluate the 
purity and concentration of DNA (54). Measurements at A260 are quantitative for relatively 
pure DNA molecules. To determine the purity of the DNA molecules the A260 and 280 ratios 
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are used.  A260/A280 ratios of 1.8 -2.0 indicates highly purified DNA (54). Proteins have an 
absorption peak at 280 nm and will reduce the A260/A280 ratio. Substances with peptide 
bonds or aromatic moieties such as proteins and phenol absorb light at A230 nm (54). 
 
Material and reagents 
 
Table 9:  Reagents used for DNA quantification. 
Reagents Purpose 
dH2O Sample blank 
DNA Quantification 
 
Table 10: Equipment used for DNA quantification. 
Equipment Model  Producer 
Pipette Reference Eppendorf 
NanoDrop NanoDrop 2000 Spectrophotometer Thermo Scientific 
 
Method 
Before quantification of DNA the NanoDrop instrument was calibrated with water as sample 
blank.  After calibration 1 μl water was measured to control the calibration before 1 μl of the 
extracted DNA was quantified.  
2.4 Polymerase Chain Reaction  
Polymerase chain reaction (PCR) was performed on all samples used for sequencing to 
produce the necessary PCR products. 
 
Principle 
PCR is an in vitro method for specific amplification of a selected sequence of DNA, into 
millions of copies. The selected sequence (template) is amplified by DNA polymerase in a 
thermal cycling process which consists of three different steps, denaturation, annealing and 
elongation. These steps are repeated 20-30 times to generate millions of copies. Denaturation 
is the first step and is performed at 94°C, the high temperature separates the double stranded 
DNA into single stranded DNA.  The annealing step follows after denaturation and the 
temperature is decreased to 45-60°C. At this temperature range primers which are short DNA 
sequences hybridizes to complementary sequences in the single stranded template. Different 
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primers have different annealing temperatures based on the length and sequence of the 
primers. Elongation is the third step and is performed at 72°C where DNA polymerase binds 
to the free 3 ` end of the primers and produces a new growing chain by incorporation of new 
nucleotides which are complementary to the template DNA. When these tree steps are 
repeated 20-30 times, millions of copies of the template sequence are produced (2). 
 
Material and reagents 
 
The primers were received from Mona Nystad and were designed in the primer3 (v 0.4.0) 
software at http://frodo.wi.mit.edu/.  In the primer design the length of the primers, annealing 
temperatures, G-C contents and complementarities to other sequences were all factors taken 
into consideration. The primer design was checked by in silico in the UCSC Genome 
Bioinformatics database at http://genome.ucsc.edu/. The gene sequence of the laverin gene 
used in primer design was retrieved from the NCBI database and the following version and 
number was used NM_173800.4. The complete gene sequence is presented in appendix C. 
 
 
Table 11: Primers used for PCR and sequencing. All primers are produced by Sigma-Aldrich.  
Forward primers are marked with F and reverse primers with R. 
Name Sequence Product size Lot. no 
LVRN ex1_1F GGGGTCTGTCTCTTCGAACC  -HA01606306 
LVRN ex1_1R TGGTCGTCACCGCTAGCTC 548 -HA01606307 
LVRN ex1_2F GGACTCAGGGACTTGGAAGC  -HA01606308 
LVRN ex1_2R ACCTGGACACGGTAGTCAGC 637 -HA01606309 
LVRN ex2-F CCAGGCTAACTTACAAGCCATC  -HA01606310 
LVRN ex2-R ACACTGCCTAGAAAAGCTACTGG 324 -HA01606311 
LVRN ex3-F GCTGGGTGACAATTGACTTGA  -HA01606312 
LVRN ex3-R CAGCCATAACCACTGGATGC 315 -HA01606313 
LVRN ex4-F TGCAGCTTCTTCTGGAAAGG  -HA01606314 
LVRN ex4-R ACCAAGGGCCCAAATAACAG 303 -HA01606315 
LVRN ex5-F GCCTTCTCTCCGTTCAGGTT  -HA01606316 
LVRN ex5-R TGAATCTGAGTCTTCCCCATTTT 451 -HA01606317 
LVRN ex6-F TTACTTAACATGCAATTACAACGAA  -HA01606318 
LVRN ex6-R TAGATAAAAAGCCTGGAATTAAAAA 373 -HA01606319 
LVRN ex7-F TTGGCATATTTCAACTCAAAGACA  -HA01606320 
LVRN ex7-R TGGATATTTGCAAGGTGAGAATTA 467 -HA01606321 
LVRN ex8_9-F GCAAAATGCAATCAGGAGCA  -HA01606322 
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Name Sequence Product size Lot. no 
LVRN ex8_9-R CAAAGCTGTTTTCCTGTGGAAC 441 -HA01606323 
LVRN ex10-F CGAGTTTCTTTTTGGAGATTGC  -HA01606324 
LVRN ex10-R AGCGGGGGTAACGCTTCT 349 -HA01606325 
LVRN ex11-F TGAGTTCTGTGTGCTATTTCATCA  -HA01606326 
LVRN ex11-R CAAGAATGATATTTTAGTTTGAAATGA 295 -HA01606327 
LVRN ex12-R GGGCGACAGAGCAAGACTC  889 -HA01606328 
LVRN ex13-F GAAGGTGCTTTATAGGCAGCAG  -HA01606329 
LVRN ex13-R ATGGCCTGTATAGACTAAATAATCAAA 268 -HA01606330 
LVRN ex14-F TCATGCATTGAAACATGGAA  -HA01606331 
LVRN ex14-R ATGGAACTAAGACTATTACTTTGGAA 358 -HA01606332 
LVRN ex15-F TCTGCCACTTGTCTATCAATGTC  -HA01606333 
LVRN ex15-R GCATATAAAATCTCTCAATGAATAACA 315 -HA01606334 
LVRN ex16-F CCCATCTTTTTATGAAACACATATTC  -HA01606335 
LVRN ex16-R GCAAAACACTCATTCCCACA 295 -HA01606336 
LVRN ex17-F TCCTACTTTTGACCTTTATATCTGTGA  -HA01606337 
LVRN ex17-R CGCAACGTTTTAATACTTACATTAGC 391 -HA01606338 
LVRN ex18-F CCTTAGAACCATGGGATTTTGA  -HA01606339 
LVRN ex18-R CTGAGCTTCCAGTGCCAAAC 291 -HA01606340 
LVRN ex19-F GGGGCCATACACTTGACCTT  -HA01606341 
LVRN ex19-R CCCTGCATTCAGGTGAGAGA 399 -HA01606342 
LVRN ex20_1F CAAACTCATGTTGCTACTTAGCATTTA  -HA01606343 
LVRN ex20_1R TCAGCAAAGAATGTGCTCCT 600 -HA01606344 
LVRN ex20_2F CCACAGAATTTACTTTAAATGTCACG  -HA01606345 
LVRN ex20_2R TTTGACATCATTGTTTTCACTCG 571 -HA01606346 
LVRN ex20_3F AGTGGGATGGACACCCTTTC  -HA01606347 
LVRN ex20_3R CCTGACACTCAGGGAGAATCC 590 -HA01606348 
LVRN ex20_4F CATACGCTCAAAGCAATGTGA  -HA01606349 
LVRN ex20_4R TGACAGCAGCACAAAATGGA 446 -HA01606350 
LVRN ex11_F1 TGAGTTCTGTGTGCTATTTCATCA  HA-01886724 









Table 12: Reagents used in PCR reactions. 
Reagents  Source 
Primer F and R Sigma-Aldrich 
Jump Start REDtaq Ready MIX Sigma Life Science 
dH2O Braun 
 
Table 13: Equipment used for PCR. 
Equipment Model  Producer 
Pipette Pipet Lite Ranin 
Centrifuge Mini Star Silver VWR 
Centrifuge Spectrafuge Mini Labnet 
Thermal Cycler MBS Satellite 0,2 Thermal Cycler Thermo Electron Corporation 
Thermal Cycler MBS 0,2S Thermo Hybaid 
Thermal Cycler MBS 0,2 G Thermo Hybaid 
 
 Method 
First gradient PCR was performed with all primers documented in table 11.  The aim with the 
gradient PCR was to find the best suited annealing temperature for all primers. The 
components and volumes used in the gradient PCR program are presented in table 14 and 
were combined in 0.2 ml PCR tubes. Before analysis a quick spin were performed on all 
samples before they were analysed at the program presented in table 15. After completion of 
the gradient PCR, two PCR programs with different annealing temperatures were designed, 
program 1 and 2 (table 16, and 17). 
 
For all PCR experiments performed with PCR program 1 or 2, one negative control were 
added for each primer to check for contamination. In this control DNA was replaced with 
sterile water. The primers used in the experiments are presented in table 11. For these PCR 
experiments the components and volumes presented in table 14 were combined in 0.2 ml PCR 
tubes. After combining the different volumes, a quick spin were performed before they were 










Table 14: Reagents used for PCR. 
Components Concentration stock solution Volume 
DNA template 20-100 ng/ µl 1-2 µl 
Primer F 10 pmol/µl 1 µl 
Primer R 10 pmol/µl 1 µl 
Jump Start REDtaq Ready MIX  5 µl 
dH2O  6-7  µl 
 
 
Table 15: The Gradient PCR program. 







7 63.4ºC  
8 65.4 ºC 
9 67.6 ºC 
10 69.0 ºC 
11 69.8 ºC 
12 70.3 ºC 
 
 
Table 16. PCR program 1 with annealing temperature at 57.8°C 
Step Temperature Time Cycles 
Denaturation 95°C 1 min 1 
Denaturation 95°C 30 sec 30 
Annealing 57,8°C 30 sec  
Extension 72,0°C 30 sec  
Final extension 72,0°C 8 min 1 











Table 17. PCR program 2 with annealing temperature at 65.4°C. 
Step Temperature Time Cycles 
Denaturation 95°C 1 min 1 
Denaturation 95°C 30 sec 30 
Annealing 65,4°C 30 sec  
Extension 72,0°C 30 sec  
Final extension 72,0°C 8 min 1 
Storage 4°C Infinite Infinite 
 
2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed on all PCR reactions to confirm the presence of 
PCR products and to control that PCR products were absent from the negative control. 
 
Principle 
Agarose gel electrophoresis is a method where DNA molecules are separated according to 
size and charge by their migration pattern in an agarose gel. 
 
DNA molecules are loaded on an agarose gel, made by combining agarose powder with an 
aqueous buffer. The agarose gel is then covered in buffer and constant voltage is applied. In 
the electric field produced by the applied voltage, negatively charged DNA molecules will 
migrate toward the positive pole. During the migration the DNA pass through pores in the 
agarose gel. The size of the pores varies according to the amount of agarose in the gel. The 
higher contents of agarose the smaller the pores are. Small DNA molecules moves faster 
trough the pores than larger ones and migrates further in the gel, separating the molecules by 
size.  How fast the molecules travel through the gel is also dependent on the voltage applied. 
To visualize the migration pattern, the gel is soaked in a dye after completion of the gel 
electrophoresis. The dye intercalates with the DNA and creates visible bands on the gel when 
enlightened with UV light. The size of the DNA molecules can then be determined by 
comparing the samples migration pattern with a ladder. The ladder is loaded on the gel 





Materials and reagents 
 
Table 18: Reagents used in electrophoresis. 
Components Producer 
UltraPure Agarose Invitrogen 
1 X TBE buffer Made at the lab (table 19) 
GelRed Nucleic Acid Gel Stain Biotium 
1 kb plus ladder Invitrogen 
 
 
Table 19: Components for the 10 X TBE  and 1 X TBE buffers. 
Contents 10 X TBE 1 X TBE 
TRIS/BASE 1080 g 108 g 
Boric acid 550g 55g 
0.5 M EDTA (pH 8) 400 ml 40 ml 
Ad aqua dest 10 000 ml 5000 ml 
Total 10 000 ml 5000 ml 
 
Table 20: Components for the 1 kb plus ladder. 
Contents Volume 
Kb-ladder 20 µl 
Loading buffer 50 µl 
1 X TE buffer 330 µl 
Total 400 µl 
 
 
Table 21: Components for the loading buffer. 
Contents Volumes 
0.25 % Bromphenol Blue 0.05 g 
0.25% Xylene cyanol 0.005 g 
40% w/v Sucrose 8.0 g 
Ad aqua dest  20 ml 
Total 20 ml  
 
Table 22: Components for the TE buffer 
Contents  10 X TE 1 X TE 
0.5 M EDTA (pH 8) 20 ml 2 ml 
TRIS/HCL 15.8 g 1.58 g 






Table 23: Equipment used for electrophoresis. 
Equipment Model Producer 
Geltray, comb and tray Wide Mini-slub cell GT BioRad 
Power supply Power Pac 300 BioRad 
Power supply Power Pac basic BioRad 




A 1.5 % agarose solution was made by combining 7.5 g agarose with 500 ml of 1 X TBE 
buffer, which was mixed and warmed in a microwave oven until all of the agarose powder 
was completely dissolved, and then stored at 65°C. To produce a firm gel the agarose solution 
was poured into a gel tray containing a comb and left to polymerize for 20 minutes. The comb 
produces the wells in the gel were the samples are loaded.  After polymerization the gel was 
placed in a tray containing 1 X TBE buffer. Ten μl of 1 kb plus ladder and 2 μl of PCR 
products were then loaded on the gel and run at 95 V for 30-60 minutes before sealing the gel 
in dye. In some analysis 4 μl of ladder and PCR products were applied on the gel. After 
completed electrophoresis the gel was soaked in a dye (GelRed) for 20 minutes to stain the 
DNA molecules. Before it was placed under UV light in a BioDoc-it imaging system for 
picture taking it was discoloured in water. By comparing the band on the 1 kb plus ladder 
with the bands from the PCR products, the size of the sample DNA was determined. 
 
2.6 ExoSAP treatment of PCR products 
 
ExoSAP was performed on all PCR products prior to sequencing. 
 
Principle 
ExoSAP is a method for cleaning of PCR products before sequencing by removal of primer 
leftovers and deoxynucleotides (dNTPs). Exonnuclease 1 removes primer leftovers while 






Material and reagents 
 
Table 24: Components in the ExoSap. 
Reagents Concentration Volume per reaction Producer 
Exonuclease 1 10 U/µl 0,5 USB 
Shrimp Alkaline Phosphatase 2 U/µl 0,5 USB 
 
 Method 
1μl of ExoSAP was added to the PCR products and run at the PCR program presented in table 
25.  
 
Table 25: PCR program for ExoSAP. 
Steps Temperature Time 
Activation 37°C 1 hour 
Inactivation 85°C 15 minutes 
Soak 4°C Infinite 
 
2.7 DNA sequencing 
DNA sequencing was performed on a selection of samples from preeclamptic patients, normal 
controls and samples from normal pregnancies. 
 
Principle 
Sanger sequencing is a method where the correct order of bases in the DNA sequence is 
determined. The basis for Sanger sequencing is use of DNA polymerase to synthesise a large 
amount of DNA fragments of variable length, by incorporation of 2`deoxynucleotides 
(dNTPs) and fluorescent labelled 2`3 `-dideoxynucleotides (ddNTPs). Primers are used to 
define the parts of the genome to be sequenced. The first step in the sequencing process is to 
denaturize the template DNA, followed by annealing of primers to complementary regions in 
the template. After hybridization of primers, DNA polymerase attaches to the primers 3 `end 
and starts to synthesis new fragments of different lengths by incorporating dNTPs and 
ddNTPs. When a dNTP is incorporated the synthesis will continue and creates a growing 
DNA strand.  Incorporation of a ddNTP terminate the synthesis because the ddNTPs lacks a 
hydroxyl group at the 3` end of the molecule. This hydroxyl group is essential for addition of 
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new molecules. Since the incorporation of dNTPs and ddNTPs is random, DNA fragments 
differing by one base pair (bp) from each other are produced. 
 
After completion of the sequencing reaction the DNA fragments are separated by size by  
capillary gel electrophoresis. The shortest molecules travel fastest through the gel and will 
first be illuminated by UV light from a laser. All DNA fragments have a ddNTP at the end 
which emits a fluorescent signal upon illumination. Each of the four ddNTPs (A, C, G and T) 
are labelled with different fluorescent colours and emits fluorescent lights with different 
spectres, revealing which type of base that is present at the end of the fragment. A computer 
program converts the emitted light into a complete sequence where all the bases in the 
sequence are presented in correct order (2, 56, 57). 
 
Material and reagents 
 
Table 26: Components used in sequencing reactions. 
Components Concentration Volume Producer 
Primer F or R 10 pmol/µl 0.5µl Sigma-Aldrich 
BigDye V.3.1  0.5µl Applied Biosystems 
5 X buffer to BigDye. V.3.1  3 µl Applied Biosystems 
dH2O  14 Braun 
PCR product  2 µl  
 
Table 27: Equipment used in sequencing reactions. 
Equipment Model Producer 
Centrifuge Mini Star Silver VWR 
Centrifuge Spectrafuge Mini Labnet 
Thermal Cycler MBS Satellite 0,2 Thermal Cycler Thermo Electron Corporation 
Thermal Cycler MBS 0,2S Thermo Hybaid 
DNA sequencer ABI PISM 3130 XL Genetic Analyzer Applied Biosystems 




The components presented in table 28 were combined in a 0.2 ml PCR tube. The amount of 
PCR product and water varied between different analyses but the total volume of the 
sequencing reaction was always 20 μl. The cyclic amplification of PCR products in the 
sequencing reaction was performed in an ordinary thermo cycler at the program presented in 
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table 29. Separation of the sequencing products were performed by capillary electrophoresis 
with ABI PRISM 3130 xl Genetic Analyzer from Applied Biosystems. 
 
Table 28:  Components used in PCR. 
Components Volume 
Primer F or R 0.5µl 
BigDye V.3.1 0.5µl 
5 X buffer to BigDye. V.3.1 3 µl 
dH2O 14 
PCR product 2 µl 
 
Table 29: The PCR sequencing program. 
Step Temperature Time Cycles 
Denaturation 96°C 10 sec  
Annealing 50°C 5 sec 30 
Extension 60°C 4 min  
Storage 4°C Infinite Infinite 
 
 
2.8 Array comparative genomic hybridization 
Array comparative genomic hybridization (aCGH) was performed on an assortment of 19 
samples from women with preeclampsia and 19 samples from normal pregnancies.  
 
Principle 
The aCGH principle is presented in section 1.6 in the introduction (page 10-11) 
 
Material and Reagents 
 
Table 30: Kits used in aCGH analysis 
Kit Lot. no  Producer 
NimbleGen Dual colour DNA labelling Kit 12888300, 12209400, 12537900 NimbleGen 








Table 31: Arrays and mixers used in the aCGH analysis. 
Arrays and 
Mixers 
Lot. no Array number Array format 
Array 090819_HG18_WG_CGH_V2_HX3 398843 3X 720K 


















Mixer 0014 HX3 
0016 HX3 
 0024 HX12 





Table 32: Equipment used in aCGH analysis. 
Equipment Model Producer 
Pipette Pipet Lite Ranin 
Centrifuge Mini Star Silver VWR 
Centrifuge Spectrafuge Mini Labnet 
Centrifuge Capselfuge PMC-060 Tommy 
Centrifuge Centrifuge 5415D Eppendorf 
Vortexer VF2 Janke og Kunkel, KA laboratorietechnik 
Thermal Cycler PTC-200 Pelter Thermal Cycler MJ Research 
MiniVac MiVac GeneVac 
Dryer NimbleGen Microarray Dryer NimbleGen 
Hybridization system Hybridization System 4 NimbleGen 
Skanner GenePix 4000B Molecular dynamics 
Water bath Ecoline Star Edition E100 Lauda 
Gas supply NimbleGen Compressed Gas Nozzle NimbleGen 
Software GenePix version 6 NimbleGen 
Software GenePix version 7 NimbleGen 
Software NimbleScan NimbleGen 











Method for 3X720K and 12X135K arrays 
 
The aCGH procedure consisted of several steps, involving, preparation of Cy3 and Cy5 
sample labelling, hybridization, washing, and scanning and data analysis (figure 6). How 
these steps were performed is documented in the following procedure where they were 
divided into different sections. A more detailed procedure regarding scanning and data 
analysis can be found in reference (58). 
 
 
Figure 6: Illustration of the different steps in the aCGH protocol presented below. 
 
Preparation of Cy3 and Cy5 for use in labelling of DNA. 
2,200 μl Random primer Buffer and 4 μl B-mercaptoethanol were combined in one vial in 
fume hood. The vials containing Cy3 and Cy5 were spun briefly and then each of them were 
diluted in 1,050 μl of the mixture of random primer buffer and B-mercaptoethanol. The 
contents in the tubes were transferred to 0.2 ml PCR tubes. Each of the tubes contained 40 μl 
of the solution and was stored at -20°C protected from light.  
 
Labelling of patient and normal control DNA 
In this step the patient DNA and reference DNA were labelled with different colours (Cy3 and 
Cy5). The labelling reaction was performed with oligo nucleotide-primed synthesis by the 
klenow enzyme. For labelling the components in table 33 were combined in PCR tubes. 
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Amount of water were adjusted after the amount of DNA added. The total volume of water 
and DNA were always 40 μl. 
 
Table 33: Components used for labelling of the DNA.  
Contents Patient sample Normal control 
DNA 1μg 1μg 
Cy5 40 μl   
Cy3  40 μl 
H2O Variable  Variable 
LHC 1 2 μl  
LHC 2  2 μl 
 
 The samples were then heat-denatured in a thermocycler at 98°C for 10 minutes and chilled 
on ice for 2 minutes. A dNTP/KLENOW master mix for each of the samples was prepared on 
ice and in a fumehood as described in table 34.  
 
Table 34: Components in the dNTP/Klenow master mix. 
dNTP/ klenow Master Mix Volume per sample 
10 mM dNTP Mix 10 μl 
PCR Grade Water 8 μl 
Klenow fragment  2 μl 
Total 20 μl 
 
Twenty μl master mix was added to each samples and the contents was mixed well by 
pipetting up and down ten times. A quick spin was performed to collect the contents in the 
bottom of the tube before the samples were incubated for 2 hours at 37°C in a thermo cycler 
protected from light. After incubation 21.5 μl stop solution was added to the samples to stop 
the labelling reaction and precipitate DNA. Hundred and ten μl isopropanol was added to the 
same number of new clean 1.5 ml tubes as the number of samples. The samples were vortexed 
briefly and spun before the contents were transferred to the 1.5 ml tubes containing 
isopropanol. After transferral to ispopropanol the tubes were vortexed well and incubated for 
10 minutes in room temperature, protected from light. To create a supernatant and form a 
pellet the samples were centrifuged at 12,000x g for 10 minutes. The supernatant was 
removed with a pipette, and 500 μl 80 % ice cold ethanol was added. Dislodge the pellet by 
pipetting a few times up and down. The samples were centrifuged at 12,000 X g for 2 minutes 
44 
 
and the supernatant was removed. A speedVac were used to dry the contents in the tubes on 
low heat protected from light until they were dry, approximately 5 minutes. After drying the 
samples were either stored at -20°C for up to 1 month or it was proceeded to the next step. 
 
Rehydration prior to hybridization 
Before opening the tubes were spun briefly, and the pellets were rehydrated by adding 35 μl 
of PCR Grade Water to each tube containing a pellet. The tubes were vortexed for 30 seconds 
and a quick spin was performed before 5 minutes incubation in room temperature protected 
from light.  When the pellets were completely rehydrated they were vortexed again and a 
quick spin was performed. The concentrations of the rehydrated samples were then quantified 
by NanoDrop. 
Hybridization 
In this step a hybridization buffer was added to the labelled samples. The hybridization buffer 
contains formamide which denaturizes the DNA and creates single stranded DNA for 
hybridization. It also prevents unspecific binding at temperatures lower than 37°C. In addition 
the hybridization buffer contains Tween 20 which minimizes unspecific background noise, 
and Dextran Sulfate which increases the DNA concentration and improves hybridization for 
optimization of the results (59). Cot1 DNA is another component in the hybridization buffer 
and hybridizes to repetitive sequences  in the labelled DNA and prevents false fluorescent 
signals (59).  
 
 The hybridization system was programmed to 42°C. Thirty one μg of test samples and 
reference samples were combined in new clean 1, 5 ml tubes for the 3X720K array and 20 μg 
for the 12X135K array. The tubes were dried on low heat and protected from light on a 
SpeedVac. Subsequently the samples were either stored at -20°C for up to one month or it 
was preceded to the next step. 
 
The dried pellets were re-suspended in 5.6 μl sample tracking control (STC) for the 3X720K 
array and 3.3 μl for the 12X135K array and vortexed before a quick spin was performed. 






Table 35: Components for the hybridization master mix. 
Components Volume for one slide (3X720K) Volume for one slide (12X135K) 
2 X hybridization buffer  35 μl 88.5 μl 
Hybridization Component A  14 μl 35.4 μl 
Alignment Oligo  1.4 μl 3.6 μl 
Total 50.4 μl 127.5 μl 
 
14.4 μl for the 3X720K array and 8.7 μl for the 12X135K array of the hybridization mix were 
added to each sample before vortexing for 15 seconds and a quick spin. Followed by 
incubation for 5 minutes protected from light at room temperature.  Afterwards the tubes were 
placed in a PCR thermal cycler (42°C) for 5 minutes and then vortexed and spun before 
loading. 
 
Assembly of mixer and array 
Before loading of samples the mixer and array were attached to each other by use of the 
PMAT (figure 7). 
 
Figure 7:  Preparation of mixer and array. The PMAT is illustrated in blue, and the array and mixer are aligned 
in the PMAT as demonstrated.  After alignment of mixer and array in the PMAT, the PMAT is closed and the 
array attatches to the mixer. Retrived from reference  (58). 
 
After assembly of the mixer and array they were removed from the PMAT and incubated in 
the hybridization system for 5 minutes.  For removal of potential air bubbles the mixer Brayer 
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was rubed over the mixer. The samples were vortexed and spun before loading 18 μl in the fill 
port on each subarray for the 3X720K array and 6 μl for the 12X135K array. Before inserting 
the mixer and array into the hybridization system, the fill and vent ports were sealed with 
mixer ports and adhered properly with the Mixer Brayer. The hybridization reaction was 
carried out in the range from 68 to 72 hours.  
 
Preparation of washing solutions 
Excess labelled DNA located on the array after hybridization can cause false fluorescent 
signals. To prevent this, the arrays were washed in washing solutions containing PBS and 
Tween20. One of the washing solutions also contains formamide (59). 
 
Before removal of the mixer and array from the hybridization system, the wash 1, 2 and 3 
solutions were prepared as presented in table 36.  Two wash 1 solutions were prepared, one 
for the bucket and one for the slide container. 
 
Table 36: Components and volumes for the washing solutions. 
Wash for one slide Wash 1 ( bucket) Wash 1,2, and 3 (slide container) 
VWR 243ml 24.3 ml 
10 X wash buffer 1,2 and 3 27ml 2.7 ml 
1M DTT 27 μl 2.7 μl 
Total 270 ml 27 ml 
 
The bucket containing wash 1 solution was preheated to 42°C while the others were kept in 
room temperature. After preparation of the washing solutions, the mixer was removed from 
the hybridization system and put into the mixer diassembly tool. The mixer disassembly tool 
was placed in the bucket containing the pre heated wash 1 solution and the mixer was 
removed from the array by carefully peeling it off. 
 
Washing procedure 
 The array was shaken in the bucket for 10-15 seconds and then transferred to the container 
with room tempered wash 1 solution, and shaken for 2 minutes. Then the array was 
transferred to the container with wash 2 solution and was shaken for 1 minute. In the last 
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washing step the array was transferred to wash 3 solution and shaken for 15 seconds before it 
was dried in the NimbleGen Microarray dryer for 2 minutes.  
 
Scanning and data analysis 
Scanning and data analysis were performed after the washing procedure was completed. 
For scanning the Genepix software was used. Five μm was used as pixel size and the whole 
array was scanned producing one image. In all scanning procedure the PMT settings for each 
colour (Cy3 and Cy5) were adjusted to produce histograms with overlapping curves. The 
curves for Cy3 and Cy5 should be overlapping for most of the histogram to produce good 
quality results. 
 
After end scanning data analysis was performed by importing the scanned image from the 
GenePix software into Nimblescan CGH software. Here each subarray on the scanned image 
was burst (separated) into a separate image, creating three images (A01-A03) for the 3X720K 
array and twelve images (A01-A12) for the 12X135K array. 
 
After separating the array into subarrays the images were grided by aligning gridmarks in 
correct position over the array. This was performed automatically by the software, but in 
some cases manual alignment was necessary.  
 
In the next step in the data analysis an experimental integrity report was made. For each 
subarray one STC was added in the hybridization step after combining one patient sample 
with one normal control. In this step one experimental report was made which documented 
the STCs present in the different arrays, as a quality control for adding the correct sample to 
the correct subarray. 
 
After control of the STCs, pair reports were created which, documents the signal intensity for 
each probe on the array. 
In the final step of data analysis CGH-segMNT reports were created. Here the data were 
normalized and copy number analysis was performed. Parameters included 5x averaging 
window, minimum number of probes equal to 2, and a log2 max/min scaling from -3 to 3. The 
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gff files produced were used in later bioinformatical analysis (section 2.9. page 48 and 49).  
Fluorescence ratio plots were made for all chromosomes on each subarray. 
2.9 Bioinformatical analysis on aCGH results 
Material 
 
Table 37: Summary over the databases used in the processing of aCGH results. 
Database Link 
CGHWeb (Childrens Hospital Program webserver) (http://compbio.med.harvard.edu/CGHweb/) 
Ensembl (R biomart package against human genome) (may2009.archive.ensembl.org) 
UCSC Genome Browser on Human Mar.2006               
(NCBI36/hg18) Assembly                     
http://genome.ucsc.edu/cgi-bin/hgGateway?db=hg18 
Database of Genomic Variants (DGV) http://projects.tcag.ca/variation/ 
 
Table 38: Summary of the algorithms used in the CGHWeB software presented above 














After generating the ggf- files they were used in bioinformatical analyses. First the gff- 
formatted reports were fed directly into the CGHWeb webserver for the analysis of CGH data. 
This service offers the distinct advantage of running several alogrithms in parallel offering 
users the ability to select results based on the consensus findings of the algorithms.   The 
algorithms used by this server are, Lowess, Wavelet, Quantreg, RunAvg, CBS, CGHseg, 




Figure 8: Presentation of the algorithms used in the CGHWeb server. On the left side of the figure the 
algorithms are documented.  The chromosome illustrates the chromosomal positions for the detected 
deletionsand duplications. Green lines represent detected deletions and orange lines duplications. 
 
Deletions and duplications detected in more than four of the presented algorithms were 
included in further analysis where consensus areas of deviation were parsed from the 
CGHweb analysis and mapped against known genes in area. Positions were mapped using R 
biomart package against human genome build 18 (may2009.archive.ensembl.org) in 
accordance with the design file supplied with the CGH arrays. Gene name, specifically 
HGNC gene name was taken from the Ensembl annotation based on chromosome name, 
probe start and probe stop.  To better review and integrate results a html- page was generated 
for each array with direct hyperlinks to the UCSC browser for areas in question, from these 
the tables in appendix A (I-XX) were made. All deleted or duplicated areas involving 5 or 
more probes were included and were documented with chromosome position, start and end 
position for the probes, number of probes, genes involved and mean values.  The mean value 
represent the average signal strength found within the window of probes.  
 
The USCS hyperlinks were used to document the chromosomal position and gene contents for 
the areas in question (CNVs).  This database also contained information on gene function and 
expression profiles for the detected genes and was used in the evaluation of their potential role 
in the pathophysiology of preeclampsia.  
 
The database of Genomic Variants (DGV) was screened for the areas in question. DGV 
presents an outline over the structural variation in the human genome and structural variants 
involving more than 1kb in size are included in this database. All variants found in samples 





3.1 DNA extraction 
Manual extraction was performed on normal controls from healthy individuals (K1-K4, M1-
M6), while automatic extraction was carried out on all samples from preeclamptic patients 
and normal pregnancies used in PCR, sequencing and aCGH analysis. For comparison of the 
two extraction methods the controls from healthy individuals were also extracted 
automatically. Following the extraction process the DNA concentration was quantified by 
NanoDrop and all plots were examined before subsequent analyses were performed on the 
extracted DNA. The two extraction methods showed similar results regarding both 
concentrations and purity. The purity was determined after evaluation of the A260 and A280 
ratios. The samples with the highest purity and concentrations were selected for succeeding 
analysis.  
 
For the normal controls the DNA concentrations were within the range of 16.0–42.5 ng/μl.  
The patients samples used in sequencing (maternal EDTA blood samples) had DNA 
concentrations in the range from 43.5–112.1ng/μl while the samples from normal pregnancies 
had concentrations from 24.0–142.0 ng/μl. The patients samples used in aCGH had 
concentrations in the range of 32.0–104.1ng/μl and the samples from normal pregnancies 
from 27.0–104.5 ng/μl 
 
3.2 Gradient PCR 
Gradient PCR was performed on DNA extracted from healthy individuals for all the primers 
used in sequencing of the laeverin gene. The controls were selected based on their 
concentration and purity after quantification with NanoDrop. Sample M6 was used for the 
primers LVRN ex 1_1F/R-3F/R, K4 for primer LVRN ex 4F/R-10F/R, K3 for primers LVRN 
ex 11F/R-16F/R, M4 for primers LVRN ex 17F/R-20_3F/R and M1 for primers LVRN ex 




For all gel pictures presented in this section, the numbers on the left side of the picture 
represent the size of the fragments of the 1 kb plus ladder used in all experiments. All gel 
pictures have some weak bands above the first visible band on the ladder. These represent 
genomic DNA present in the PCR products. All primers were run at the same PCR gradient 
program which is presented in table 15. The PCR products from the different annealing 
temperatures were loaded on the gel in the same order as the gradient PCR program.  The first 
well on the gel pictures always contains PCR products from annealing temperature 55.5°C 




Figure 9: Well (1) 1 kb plus ladder, well (2) empty well, well (3)-(14) primer LVRN ex1_1F and ex 1_1R, Well 
(15) empty well, Well (16)-(27) primer LVRN ex 1_2F and ex 1_2R.  
 
 
Figure 10: Well (1) 1 kb plus ladder, Well (2) empty well, Well (3-14) Primer LVRN ex 2F and ex 2R, Well 












Figure 11: Well (1) 1 kb plus ladder  Well (2) empty well , Wells (3)-(14) primer LVRN ex 4F and ex 4R,  Well 




Figure 12: Well (1) 1 kb plus ladder well (2) empty well, wells (3)-(14) Primer LVRN ex 6F and ex 6R (15) 




Figure 13: Well (1) 1 kb plus ladder well (2) empty well, wells  (3)-(14) primer LVRN ex8_9F and ex 8_9R, 





Figure 14: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) Primer LVRN ex11F and ex 11R (15) 




Figure 15: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) primer LVRN ex 13F and ex 13R, well 




Figure 16: Well (1) 1 kb plus ladder , well (2) empty well, wells (3)-(14) primer LVRN ex 15F and ex 15R , 







Figure 17: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) Primer LVRN ex 17F and ex 17R, well 
(15) empty well, wells (16)-(27) primer LVRN ex 18F + ex 18R 
 
Figure 18: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) primer LVRN ex 19F and ex 19R, well 




Figure 19: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) Primer LVRN ex 20_2F and ex 20_2R 





Figure 20: Well (1) 1 kb plus ladder, well (2) empty well, wells (3)-(14) primer LVRN ex 20_4F and ex 20_4R 
well (15) empty well, wells (16)-(27) Primer LVRN ex 11_F1 and ex12_R2 
  
Table 39 was based on evaluation of all documented gel pictures. All primers were presented 
with the temperatures which produced their specific bands and the selected PCR program. In 
addition the temperatures which produced unspecific bands and to weak bands for subsequent 
analysis were included. Temperatures where no PCR products were produced were included 
in the column for weak bands. 
 
Table 39: Summary of results from the gradient PCR experiments. Each primer is presented with the annealing 
temperatures providing their specific bands, unspecific bands and the temperatures where no bands were 
detected. The bp size for all bands is documented in addition to the PCR program selected for each primer. The 
annealing temperature for PCR program 1 is 57.8 °C and for program 2, 65.4°C 
Primers  Specific bands 
(Size) 
Unspecific bands  
(size ) 
Weak bands PCR 
program 
LVRN ex 1_1F/R 55.5°C -70.3°C (548 bp) 55.5ºC -56.5ºC (1000 bp) 
55.5ºC -70.3ºC (850 bp) 
- 2 
LVRN ex 1_2F/R 55.5°C -70.3°C(637bp) 55.5ºC-56ºC (1,650bp) 
55.5°C -57.8ºC (1000bp) 
- 2 
LVRN ex 2F/R 55.5ºC -67.6ºC (324 bp) 55.5-67.6 ºC (350bp) 69.0ºC -70.3ºC 1 
LVRN ex 3F/R 55.5°C -67.6°C (313bp) - 69.0ºC -70.3ºC 1 
LVRN ex 4F/R 55.5ºC.65.4ºC (303 bp) 55.5°C -63.4°C (250bp)  67.6ºC-70.3ºC 1 
LVRN ex 5F/R 55.5°C -65.4°C (451bp) 55.5°C -63.4°C (500bp) 67.6ºC -70.3ºC 1 
LVRN ex 6F/R 55.5°C -61.4ºC (373) 55.5°C -59.5°C (450bp) 61.4ºC -70.3ºC 1 
LVRN ex 7F/R 55.5ºC -61.4ºC (467) 55.5°C -61.4°C (550bp) 63.4°C -70.3ºC 1 
LVRN ex 8_9F/R  55.5ºC -65.4ºC (441bp) - 67.6°C -70.3ºC 1 
LVRN ex 10/R 55.5ºC -65.4ºC (349bp) - 67.6°C -70.3ºC 1 
LVRN ex 11F/R 55.5ºC -59.5ºC (295bp) 55.5°C -59.5°C (350bp) 61.4ºC -70.3ºC 1 
LVRN ex 11F 
/12R 
- 55.5ºC -70.3ºC - - 
LVRN ex 13F/R 55.5ºC -63.4ºC (295bp) 55.5°C -63.4°C (330bp) 65.4ºC -70.3ºC 1 
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Primers  Specific bands 
(Size) 
Unspecific bands  
(size ) 
Weak bands PCR 
program 
LVRN ex14F /R 55.5ºC 5-61.4ºC (358bp) 55.5°C -59.5°C (400bp) 63.4ºC -70.3ºC 1 
LVRN ex 15F/R 55.5ºC -61.4ºC (315bp) 55.5°C -59.5°C (400bp) 63.4ºC -70.3ºC 1 
LVRN ex 16F/R 55.5ºC -61.4ºC (295bp) - 63.4ºC -70.3ºC 1 
LVRN ex 17F/R 55.5ºC -63.4ºC (391bp) 55.5°C -63.4°C (500bp) 65.4ºC -70.3ºC 1 
LVRN ex 18F/R 55.5ºC -63.4ºC (291bp) 55.5ºC -63.4ºC (350bp) 65.4ºC -70.3ºC 1 
LVRN ex 19F/R 55.5ºC -67.6ºC (399bp) 55.5ºC -59.5ºC (900bp) 
55.5 ºC -61.4 ºC(200,300bp) 
69.0ºC-70.3 ºC 2 
LVRN ex 20_1F/R 55.5ºC -65.4ºC (590bp) 55.5ºC -65.4ºC (650bp) 
55.5°C-61.4°C (400,500bp) 
67.6ºC -70.3ºC 1 
LVRN ex 20_2F/R 55.5ºC -63,4 ºC (571bp) - 65.4ºC -70.3ºC 1 
LVRN ex 20_3F/R 55.5ºC -67,6ºC (590bp) 55.5ºC -63.4ºC (400,500bp) 69.0-70.3ºC 2 
LVRN ex 20_4F/R 55.5ºC -65.4ºC (446bp) - 67.6ºC -70.3ºC 1 
LVRN ex 11_F1/ 
12R2 
55.5ºC -67.6ºC (754bp) 55.5ºC -65.4ºC (500bp) 69.0ºC -70.3ºC 2 
 
3.3 Polymerase chain reaction 
The aim with the PCR experiments was to produce products for sequencing. After designing 
the two different PCR programs, PCR were performed on all samples prior to sequencing. 
The selected samples for PCR and sequencing were chosen after estimation of their 
concentrations and purity after quantification by NanoDrop. All samples had acceptable 
concentrations and ratios and the selected assortment was randomly chosen. PCR products for 
all exons and parts of introns in the laeverin gene were produced for the sample numbers 3P, 
5P, 15P, 20P, 24P, 25P, 26P, 32P, M6, K4, 35N, 19 and 20. Furthermore PCR products for 
exon 7 and 10 were made from 20 samples from preeclampsia patients and 18 samples from 
normal pregnancies. In addition, PCR products for exon 7 were produced for 23 samples from 
normal pregnancies. 
 
 Negative water controls were applied for all primers in each experiment to examine if the 
samples were contaminated. After completion of the PCR experiments, gel electrophoresis 
was performed on all PCR products to investigate it there was PCR products in the negative 
control and to control that PCR products were present for all samples. Figure 21 documents 
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one representative gel electrophoresis performed on PCR products from preeclampsia patients 
with primer LVRN ex 10F/R. 
 
 
Figure 21: Well (1) 1 kb plus ladder well (2) empty well, well (3) 1P well (4) 2P well (5) 4P well (6) 6P well (7) 
7P well (8) 8P well (9) 9P well (10) 10P well (11) 11P well (12) 12P well (13) 13P well (14) 14P well (15) 16P 
well (16) 17P well (17) 18P well (18) 19P well (19) 21P well (20) 22P well (21) 23P well (22) 20P well (23) 8N 
well (24) H2O (negative control) 
 
At the top of the wells some genomic DNA is present.  PCR products were present in wells 3-
23. In well 24 no bands are detected and the control is negative, indicating that there is no 
contamination of DNA.  
 
3.4 DNA sequencing 
3.4.1 Sequencing of DNA from maternal blood samples 
An assortment of DNA samples extracted from maternal blood samples of preeclampsia 
patients and normal pregnancies were selected for sequencing. All samples had acceptable 
concentrations and purity and were randomly selected after DNA quantification with 
NanoDrop. Sample number 3P, 5P, 15P, 20P, 24P, 25P, 26P, 32P, M6, K4, 35N, 19 and 20 
were sequenced for all exons in the laeverin gene including small parts of the introns. Twenty 
samples for preeclampsia patients and 18 samples from normal pregnancies were sequenced 
for exons 7 and 10. In addition 23 samples were sequenced for only exon 7. Detected variant 
from this sequencing analysis are presented in table 40.  Normal sequences without variants 










Table 40: Summary of detected variants from sequencing of the laeverin gene on DNA extracted from blood 
samples. (Het) is an abbreviation for a heterozygote variant while (Homo) is an abbreviation for a homozygote 
variant. The guidelines for the HGVS nomenclature retrieved from reference (60). 
Location HGVS nomenclature Sample number Protein change 
LVRN Exon 1 g.-83 G›C (Het) 3P, 5P, 24, M6, 26P, K4 Untranslated region 
LVRN Exon 1 g.-83 G›C (Homo) 15P, 20P, 32P, 35N, 25P, 19,20 Untranslated region 
LVRN Exon 1 g. 64 C› T (Het) 3P, 5P, 24P, M6,26P, K4 None 
LVRN Exon 1 g. 64 C› T (Homo) 15P, 20P, 32P, 35N, 25P, 19,20 None 
LVRN Exon 1 g. 161 T› C (Het) 3P, 5P, 24P, M6, 26P, K4 p.Lys54Ser 
LVRN Exon 1 g. 161 T› C (Homo) 15p, 20P, 32P, 35N, 25P, 19,20 p.Lys54Ser 
LVRN Exon 1 g. 204 A› G (Het) 3P, 5P, 24P, M6, 26P, K4 None 
LVRN Exon 1 g. 204 A› G (Homo) 15P, 20P, 32P, 35N, 25P, 19,20 None 
LVRN Exon 1 g. 663 C›T (Het) 24P, M6, 26P, K4 None 
LVRN Exon 1 g. 663 C›T (Homo) 15P, 32P, 35N, 25P, 19 None 
LVRN Exon 7 g. 1459 G›A (Het) 20P p.Glu487Lys  
LVRN Exon 10 g. 1746 T› C (Het) 3P, 20P, 11P, 12P, 18P, 19P, 21P, 
23P,1N, 5N, 6N, 12N, 14N, 18N, 
21N 
None 
LVRN Exon 10 g. 1746 T› C (Homo) 16P, 2N, 10N, 17N None 
LVRN Intron 12 g.2037+9A(-A›G) (Het) 3P, 5P, 20P, 24P,  M6 None coding 
LVRN Intron 12 g.2037+9A (- A›G) (Homo) 15P, 32P, 35N None coding 
LVRN Exon 13 g. 2040 G›T (Het) 3P, 5P,20P,24P, M6 None 
LVRN Exon 13 g. 2040 G›T (Homo) 15P, 32P, 35N, 26P,19, 20, K4, 
25P  
None 
LVRN Exon 13 g.2067 G› C (Het) 3P, 5P, 20P, 24P, M6 p.Leu 689Phe 
LVRN Exon 13 g.2067 G› C (Homo) 15P, 32P, 35N, 26P, 19, 20, 
K4,25P 
p.Leu 689Phe 
LVRN Intron 17 g. 2618 + 34- T›G (Het) 3P, 15P, 24P None coding 
LVRN Intron 17 g. 2618+ 34- T›G (Homo) 5P, 32P, 35N, M6 None coding 
LVRN Exon 20 g.3306 (*3) A›G (Het) 3P, 24P, 32P, 35N, 20, K4, 25P, 
20 
None 
LVRN Exon 20 g.3306 A›G (Homo) 5P, M6, 26P, 19 None 
LVRN Exon 20 g.3377(*74)  T›C (Het) 15P,  24P None 
LVRN Exon 20 g. 4439(*1136) T›G (Het) 25P  
 
After sequencing of all exons and parts of introns in the sample numbers presented above, 
only two of the variants documented in table 40 were found exclusively in samples from 
preeclamptic patients in translated exons. These variants were in exon 7, position g. 1459G›A 
and in exon 10 position g. 1746T› C.  Electropherograms documenting these two variants are 
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presented in figures 22 and 23.  Twenty samples from preeclamptic patients and 18 samples 
from normal pregnancies were screened for these variants. The variant in exon 10 was 
detected in seven more samples from preeclampsia patients and in 10 samples from normal 
pregnancies and was considered as a normal variant. The variant detected in exon 7 did not 
occur in any samples from normal pregnancies or controls. Furthermore 23 samples from 
normal pregnancies were sequenced for exon 7. None of these contained the variant and the 
variant is therefore a potential pathogenic mutation.  
 
 
Figure 22:  The left side of the figure is an electropherogram from Applied Biosystems seqscape software 
illustrating the heterozygote variant found in exon 7 position g.1459G>A in sample 20P. The two arrows 
illustrates that one A nucleotide is present at both strand in addition to one G nucleotide in this position. The G 
nucleotide is normally present alone at this position in the genome. Right side of the figure is an 
electropherogram from Applied Biosystems seqscape software illustrating the normal sequence of exon 7, 







Figure 23: The left side of the figure is a electropherogram from Applied Biosystems seqscape software 
illustrating the heterozygote variant found in exon 10 position g.1746T>C in sample 3P and 20P. The two arrows 
indicate the presence of both one C and one T nucleotide at this position. The right side illustrates the 
homozygote normal sequence for exon 10 position g.1746. The two arrows document the presence of only one T 
nucleotide at this position. 
 
 
To investigate the effect of the potential pathogenic mutation in exon 7 the amino acid 
substitution caused by the mutation was documented. Figure 24 presents the normal amino 
acid composite for the laeverin gene. According to this one Glutamic acid is replaced with 


























10 20 30 40 50 60 
MGPPSSSGFY VSRAVALLLA GLVAALLLAL AVLAALYGHC ERVPPSELPG LRDLEAESSP 
70 80 90 100 110 120 
PLRQKPTPTP KPSSARELAV TTTPSNWRPP GPWDQLRLPP WLVPLHYDLE LWPQLRPDEL 
130 140 150 160 170 180 
PAGSLPFTGR VNITVRCTVA TSRLLLHSLF QDCERAEVRG PLSPGTGNAT VGRVPVDDVW 
190 200 210 220 230 240 
FALDTEYMVL ELSEPLKPGS SYELQLSFSG LVKEDLREGL FLNVYTDQGE RRALLASQLE 
250 260 270 280 290 300 
PTFARYVFPC FDEPALKATF NITMIHHPSY VALSNMPKLG QSEKEDVNGS KWTVTTFSTT 
 310 320 330 340 350 360 
PHMPTYLVAF VICDYDHVNR TERGKEIRIW ARKDAIANGS ADFALNITGP IFSFLEDLFN 
370 380 390 400 410 420 
I S Y S L P K T D I IALPSFDNHA MENWGLMIFD ESGLLLEPKD QLTEKKTLIS YVVSHEIGHQ 
430 440 450 460 470 480 
WFGNLVTMNW WNNIWLNEGF ASYFEFEVIN YFNPKLPRNE IFFSNILHNI LREDHALVTR 
490 500 510 520 530 540 
AVAMKVENFK TSEIQELFDI FTYSKGASMA RMLSCFLNEH LFVSALKSYL KTFSYSNAEQ 
550 560 570 580 590 600 
DDLWRHFQMA IDDQSTVILP ATIKNIMDSW THQSGFPVIT LNVSTGVMKQ EPFYLENIKN 
610 620 630 640 650 660 
RTLLTSNDTW IVPILWIKNG TTQPLVWLDQ SSKVFPEMQV SDSDHDWVIL NLNMTGYYRV 
670 680 690 700 710 720 
NYDKLGWKKL NQQLEKDPKA IPVIHRLQLI DDAFSLSKNN YIEIETALEL TKYLAEEDEI 
730 740 750 760 770 780 
IVWHTVLVNL VTRDLVSEVN IYDIYSLLKR YLLKRLNLIW NIYSTIIREN VLALQDDYLA 
790 800 810 820 830 840 
LISLEKLFVT ACWLGLEDCL QLSKELFAKW VDHPENEIPY PIKDVVLCYG IALGSDKEWD 
850 860 870 880 890 900 
ILLNTYTNTT NKEEKIQLAY AMSCSKDPWI LNRYMEYAIS TSPFTSNETN IIEVVASSEV 
910 920 930 940 950 960 
GRYVAKDFLV NNWQAVSKRY  GTQSLINLIY TIGRTVTTDL QIVELQQFFS NMLEEHQRIR 
970 980 990    
VHANLQTIKN ENLKNKKLSA RIAAWLRRNT    
 
Figure 24: Presentation of the amino acid sequence for the laeverin gene. The amino acids in the M1 motif are 
presented in green. The underlined amino acid is hydrophobic residues corresponding to a transmembrane 
domain. The amino acid marked in red for position 487 is replaced with Lysine in the possible pathogenic 
mutation detected in exon 7. The amino acid marked in red in position 455 is the amino acid replaced with 
Arginine in exon 6 in the variant detected in the placenta sample. Modified from reference (46). 
 
 
3.4.2 Sequencing of DNA from placental tissue  
Sample 15P collected from placental tissue were sequenced for all exons including small parts 
of the introns for the laeverin gene. This sample originates from the same person as sample 
15P collected from EDTA blood. The results from this sequencing are documented in table 









Table 41: Summary of variations found in sample 15P from placenta tissue sequenced for all exons and parts of 
the introns in the laeverin gene. The guidelines for the HGVS nomenclature is retrieved from reference (60) The 
normal controls which the placental samples are compared with are from maternal blood samples. (Het) is an 
abbreviation for a heterozygote variant while (Homo) is an abbreviation for a homozygote variant. Variants 
detected in normal controls are marked with +. Variants which are not detected in normal controls are marked 
with -. 
Location HGVS nomenclature Protein change Detected in normal 
controls  
LVRN Exon 1 g -41 G›C (Het) Untranslated region  
LVRN Exon 1 g.64 C›T (Het) None + 
LVRV Exon 1 g.162T› C (Het) p.Leu54Ser + 
LVRN Exon 1 g.204 A›G (Homo) None + 
LVRN Exon 1 g.664 C›T (Het) None + 
LVRN Exon 6 g.1365 A›G (Het) p.Leu455Arg -  
LVRN Intron 12 g2037+9-A›G (Homo) Possible splice site change + 
LVRN Exon 13 g.2040 G› T (Homo) None + 
LVRN Exon 13 g.2068 G›C (Homo) p.Leu689Phe + 
LVRV Exon 20 g.3307 (*3)A›G (Het) After  translation termination + 
LVRN Exon 20 g.3378 (75*)T›C (Het) After  translation termination - (15P,24P) 
 
Only the variants found in exon 6 at position g.1365A›G (figure 25) and exon 20 g.3378 
(75*)T›C were found exclusively in placental tissue. The variant in exon 20 is after 
termination of translation and is therefore not considered to be significant. The placenta tissue 
contains fetal DNA, while the other sequenced preeclampsia samples, normal controls and 
samples from normal pregnancies contains maternal DNA. In the variant detected in exon 6   
the amino acid Lysine is replaced with Arginine which both are hydrophilic amino acids. 
 
 
Figure 25: Electropherogram from Applied Biosystems seqscape software illustrating the difference between the 
forward and reverse strand in the sequence from the placenta tissue. At the bottom strand the arrow illustrates the 
presence of one G nucleotides in addition to one A nucleotide. In the upper strand this G nucleotide is absent. 
The area of the green spike in the bottom half of the electropherogram is only half the area of the one in the 




3.5 aCGH results 
aCGH is sensitive to DNA quality thus an assortment of 19 samples from preeclamptic  
patients and normal pregnancies were selected based on DNA concentration and purity. In 
total eight aCGH experiments were performed according to the procedure presented in section 
2.8 and 2.9 (page 47-49). The arrays used in these experiments are presented below and in 
table 31.   
 
 
Array Formats 3X720K  
The numbers on the arrays with the 3X720K format used in the experiments were, 39884, 
461642,461643,461641, and 461678 
 
Array format 12X135K arrays 
The numbers on the arrays with the 12X135K format used in the experiments were, 
461424,509338, and 514596 
 
All analyzed 3X720K arrays contained a mixture of DNA from umbilical cord blood from 19 
patients with preeclampsia compared with umbilical cord blood from 19 women with normal 
pregnancies. This DNA mixture was analyzed in triplicate on the A01, A02 and A03 
subarrays. On the 12X135K arrays nineteen samples from preeclamptic women were 
analyzed separately against mixture of nineteen samples from normal pregnancies. 
 
To measure the reproducibility between arrays and within one array parallels of some samples 
were included. Samples 12P and 21P were analyzed in duplex on array number 514596, while 
sample 9P was analyzed on array number 509338 and number 514596.  The results from array 
number 461424 were excluded due to problems with hybridization and all samples were re-
analyzed at array number 509338. Table 42 is a summary over samples analyzed on the 















A01 2P 2P 4P 
A02 4P 4P 9P 
A03 7P 7P 12P 
A04 8P 8P 12P 
A05 9P 9P 21P 
A06 10P 10P 21P 
A07 12P 12P 23P 
A08 13P 13P 24P 
A09 15P 15P 25P 
A10 16P 16P 26P 
A11 17P 17P 30P 
A12 20P 20P 33P 
 
3.5.1 Images of the arrays 
The Arrays were scanned using the Genepix software as described in section 2.8 (page 47). 
Subsequent to scanning the images were inspected for occurrence of potential air bubbles or 
other artifacts, which may cause problems in the data analysis. Furthermore the distribution 
pattern for Cy3 and Cy5 were examined. 
 
The scanned images from the experiments are presented below. Array numbers, 39884, 
461642, and 461643 were analyzed at 10 μm in pixel size instead of 5 μm due to a default 
setting in the Genepix software. The results from these analyses were therefore excluded and 
are not presented in this thesis. The images from the 12x135K arrays are in this section 















Figure 26: Scanned image of the 461641 array. The different subarrays are labelled with A01, A02 and A03.  
All three subarrays have an uneven distribution of Cy5, while Cy3 is distributed over the whole subarrays. 
Distinct red gradients and clear green areas are present at many locations on all subarrays. A01 has some black 
artefacts  present at the bottom of the picture. A03 has the same kind of black artefacts present at the upper part 
of the subarray. 
 
Figure 27: Scanned image from the 461678 array. The different subarrays are labelled with A01, A02 and A03. 
All three subarrays have a yellow colour and an evenly distribution of Cy3 and Cy5. The A01 and A03 subarrays 
have a red gradient present at the right side and the two bottom corners. A03 has a distinct red gradient and a 






Figure 28: Scanned image with the A12-A01 subarrays from the 461424 array. A12 and A04 have a distinct red 
gradient at the top of the image and the array is greener above the gradient. A black mark is also present on A12. 
A11, A03 and A01 have a distinct red gradient at the top of the image and on the right side with green areas 
missing Cy5. A11 has also one black mark present. The A10 array has a darker colour than the others and has a 
distinct red gradient at the top left corner. One large air bubble is detected at the upper half. A09, A07 and A05 
have a clear red gradient at the upper right corners and on the right side and seem to have one air bubble present. 
The A08 and A06 subarrays have more or less an even distribution of Cy3 and Cy5. The top left corner has a 







Figur 29: Scanned images of the A12-A01 subarrays of the 509338 array. All of the subarrays seems to have an 
evenly distribution of Cy3 and Cy5. The A11 subarray however has a more green like colour than the three 
others. A12 and A11 have black artifacts present at the top of the array. A10 has a black air bubble located at the 
upper half of the subarray. A07 has a more red like colour than the others. At the center of this subarray there is a 






Figure 30: Scanned image of subarrays A12-A01 from array 514596.A12-A09 have an uneven distribution of 
Cy5. A red gradient is present at several locations.  A12 and A11 have some black artefacts present. Array A08 
and A06 have an evenly distribution pattern for both Cy3 and Cy5 over the whole subarray. A07 has a distinct 
red gradient on the right side, and over large parts of rest of the subarray the red colour are unevenly distributed. 
A05 has a large distinct red gradient to the right on the subarray. Over the rest of the subarray the colours seems 
to be evenly distributed. In A04, A02 and A01 Cy3 and Cy5 equally distributed over the whole array. A03 has a 






The results from array 461641 and 461424 were discarded after evaluation of the scanned 
images, (figures 26 and 28) due to hybridization problems with Cy5. Cy5 was absent from 
many areas on these arrays. 
 
 
3.5.2 Processing of data from the aCGH analysis. 
After scanning of the arrays data analysis was performed. Sample tracking, pair and CGH-
segment reports were created as described in section 2.8 (page 47and 48). The sample 
tracking report was controlled to document correct loading of samples on the arrays and pair 
reports were used for evaluation of the signal intensity of Cy3 and Cy5. Arrays with large 
variations in signal intensities throughout the whole array were discarded. For arrays with 
acceptable intensity of Cy3 and Cy5 bioinformatics were performed as explained in section 
2.9 (page 48 and 49). All detected copy number variants was screened in the DGV database 
and none of them were detected in this database. They were therefore considered to be 
potential pathogenic mutations. DGV contains information from healthy normal individuals, 
but it is not stated in this database whether some of the healthy individuals have had 
preeclampsia.   
 
The amount of detected copy number variants was too large for presentation of all results in 
this section. Therefore all detected CNVs were documented in appendix A with results tables 
made from the html- files. The tables in appendix A (page I-XXI) includes the CNV 
chromosome position, probe position, gene contents and mean values. After thorough 
evaluation of all detected CNVs, those with the greatest interest were selected for presentation 
in section 3.5.3. For this assortment of CNVs, fluorescence ratio profiles and the UCSC link 
from the bioinformatical analysis were documented.  
 
3.5.3 Presentation of the most interesting findings 
 
In this section the CNVs which contain the most interesting genes documented by the aCGH 
analyses are presented (table 43).  The CNVs and their genes were selected based on their 
gene contents, gene functions, and which organs the genes were expressed in. Genes 
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expressed in placenta, testis, ovaries and cancer were most interesting because they might be 
involved in pathways leading to development of preeclampsia. All CNVs contained more than 
one gene and an overview of the rest of the gene contents for these CNVs is presented in 
appendix A (page I-XXI). Some findings were detected in many of the preeclamptic patients, 
but with some variation regarding the start and stop position for the probes.  
 
 
Table 43: Presentation of the detected CNV`s with the most interesting findings regarding their gene content. 
The red colour for the mean value column document that the copy number variant is a deletion and the green 
colour that it is a duplication. 
Position Sample Probe 
position 
Gene Gene function Mean 
1q31.3 17P 19486999 
195129999 
CFHR1 Suggested involvement in 
complement and tissue invasion. 
-0,41 
7q11.23 17P 72019999 
72409999 
 
FKBP36 Member of the immunophilin protein 
family which participates in 
immunoregulation, protein folding 
and trafficking 
-0,45 
8q24.3 24P 143552499 
144137499 
BAI1 Angiogenesis inhibitor which may 
belong to the secretin receptor 
family.  
0,205 
8q24.3 24P 143552499 
144137499 
PSCA Encodes  for a 
glycosylphospahtidylinositol-
anchored cell membrane protein. 
0,205 
15q11.1-q11.2 15P 18394999 
21059999 
POTEB Belongs to the ankyrin domain 
family involved in maintenance of 
the cell membrane 
-0,24 
15q11.1-q11.2 15P 18394999 
21059999 







Catalyzes the fusion of transport 
vesicles within the Golgi cisternae.  
0,38 
 
17q21.31-q21.32 9P 41794999 
42119999 
NSF Catalyzes the fusion of transport 
vesicles within the Golgi cisternae. 
-0,45 
19q13.31 Mix 48162499 
48299999 
PSG6 Encodes for human pregnancy-




 In this section one fluorescence ratio profile is presented for all of the selected CNVs. In 
addition the results from the UCSCs genome browser are presented to document the involved 
genes and the size of the variants. Information about the UCSC database is presented in 
section 2.9. (page 48-49) The information presented regarding the gene functions in this 
section are also retrieved from the UCSC database. 
 
CNV 17q21.31-q21.32.  
The copy number variants arr17q21.31q.21.32(41599999-42119999)x1 and 
arr17q21.31q.21.32(41599999-42119999)x3 were documented in umbilical cord blood from 
fetuses of preeclampsia patients. Figures 32 and 34 presents the fluorescence ratio profiles for 
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samples 2P and 9P. The size of the CNV is 200 Kb for sample 2P and100 Kb for sample 9P 
(figure 31 and 33) and several genes are involved in these areas. According to the USCS 
genome browser NSF encodes for an N-Etylmaleimide-sensitive fusion protein which is 
essential in vesicle mediated transport. The function of this protein is to catalyze fusion of 
transport vesicles in the Golgi cisterna and between endoplasmatic reticulum and the Golgi 
stack. There are some indications for involvement of this protein in transportation of cargo 
proteins in the Golgi apparatus independent of their vesicle origin. 
  
Figure 31:  Illustration of genes involved in the CNV in chromosome position 17q21.31-q21.32 from sample 2P. 
Genes are linked to the UCSC- database and chromosomal position for each detected CNV. An illustration of the 
chromosome shown at the top of the figure with a red box marking the position of the CNV. Below the 
chromosome all genes in the detected CNV are documented. The function of these genes are presented by 
clicking on the gene name for the genes with a known function.  
 
Figure 32: Fluorescence ratio profile over the CNVs detected for chromosome 17 in sample 2P analyzed with 
the 509338 array. To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 




Figur 33:Illustration of genes involved in the CNV in chromosome position 17q21.31-q21.32  from sample 9P. 
Genes are linked to the UCSC- database and chromosomal position for each detected CNV. An illustration of the 
chromosome shown at the top of the figure with a red box marking the position of the CNV. Below the 
chromosome all genes in the detected CNV are documented. The function of these genes are presented by 





Figure 34: Fluorescence ratio profile over the CNVs detected for chromosome 17 in sample 9P analyzed with  
the 509338 array. To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 




The CNV arr7q11.23(72019999-72409999)x1 was deleted in sample 17P while the CNV arr 
7q11.23(72019999-72409999)x3 was duplicated in several of the fetuses of preeclamptic 
patients. In sample 17P the size of CNV is 100Kb and contains several genes (figure 35). The 
mean value for this CNV is -0.45 and figure 36 documents that the log2ratio is around 0.5 
indicating one copy number variation. After examination of the documented genes by the 
UCSCs genome browser the FKBP36 gene were considered to be of special interest. 
According to the UCSC genome browser FKBP36 belongs to the immunophilin protein 
family which participates in immunoregulation and basic cellular processes such as protein 
folding and trafficking. The orthologous gene in mouse is essential in fertility and 
homologous pairing in male meiosis. In humans FKBP36 is highly expressed in testis.  
 
 
Figur 35: Illustration of genes involved in the CNV in chromosome position 7q11.23 from sample 17P. Genes 
are linked to the UCSC- database and chromosomal position for each detected CNV. An illustration of the 
chromosome shown at the top of the figure with a red box marking the position of the CNV. Below the 
chromosome all genes in the detected CNV are documented. The function of these genes are presented by 




Figure 36: Fluorescence ratio profile over the CNVs detected for chromosome 7 in sample 17P with the 509338 
subarray. To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 




The CNV arr15q11.1-q11.2(18394999-21059999)x1 was detected in umbilical cord blood  of 
several of the fetuses of preeclamptic patients with varying mean values and log2ratios.  In 
sample 15P this CNV involves a deleted region on 1Mb and has a mean value on -0.24. In 
sample 10P the mean value for this mutation is- 0.42 and the size of the mutation is 500 kb. 
After examination of all genes involved in the CNV in both samples, POTEB and GOLGA8E 
were selected for further investigations. 
According to the UCSC genome browser POTEB is expressed in prostate, ovaries and testis, 
and belongs to the ankyrin domain family which are involved in the maintenance of the cell 




Figur 37: Illustration of genes involved in the CNV in chromosome position 15q11.1-q11.2 from sample 15P. 
Genes are linked to the UCSC- database and chromosomal position for each detected CNV. An illustration of the 
chromosome shown at the top of the figure with a red box marking the position of the CNV. Below the 
chromosome all genes in the detected CNV are documented. The function of these genes are presented by 





Figure 38: Fluorescence ratio profile over the CNVs detected for chromosome 15 on sample 15P analysed with 





The CNV arr19q13.31(48162499-48299999)x1 was detected in one parallel on the 461678 
array. This array contains a mixture of 19 umbilical cord blood from foetuses of preeclamptic 
patients analyzed in triplicate, see section 3.5. The CNV was detected in the A01 parallel. The 
size of the mutation is 50kb and the mean value is - 0.24. All genes involved in this CNV 
belong to the human pregnancy-specific glycoproteins (PSGs). According to the UCSC 
genome browser this group of proteins is mainly produced in large amounts by the placental 
syncytiotrophoblasts during pregnancy and is released into the maternal circulation. The 
syncytiotrophoblast are essential in placenta development. The pregnancy- specific 
glycoproteins includes a subgroup of the carcinoembryonic antigen (CEA) family that belongs 
to the immunoglobulin family.  
 
 
Figur 39: Illustration of genes involved in the CNV in chromosome position 19q13.31from a mixture of 
nineteen preeclampsia patients. Genes are linked to the UCSC- database and chromosomal position for each 
detected CNV. An illustration of the chromosome shown at the top of the figure with a red box marking the 
position of the CNV. Below the chromosome all genes in the detected CNV are documented. The function of 






Figure 40: Fluorescence ratio profile over the CNVs detected for chromosome 19 on subarray A01 on with 
461678 array.  To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 




CNV arr1q31.3(19486999-1951299999)x1 was detected in sample 17P. The size of the 
mutation is 100 kb and the mean value is -0.41. The genes included in this mutation are 
presented in figure 41. The CFHR1 gene encodes for a protein belonging to the complement 
factor H protein family. In reference to the genome browser the protein binds to Pseudomonas 
aeruginosa elongation factor Tuf in collaboration with plasminogen. It is suggested that Tuf 
acts as a virulence factor by acquiring host proteins to the pathogen surface and in this way 
controls complement and tissue invasion. CFHR1 is highly expressed in several organs 
included the fetal liver.  The other genes represented in this deletion (figure 41) are involved 
in the complement system.   
 
 
Figur 41: Illustration of genes involved in the CNV in chromosome position 1q31.3 from sample 17P. Genes are 
linked to the UCSC- database and chromosomal position for each detected CNV. An illustration of the 
chromosome shown at the top of the figure with a red box marking the position of the CNV. Below the 
chromosome all genes in the detected CNV are documented. The function of these genes are presented by 






Figure 42: Fluorescence ratio profile over the CNVs detected on chromosome 1 on subarray A11 from the 
509338 array. To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 
documented. The red arrow documents the deletion.  
 
CNV 8q24.3 
CNV arr8q24.3(143552499-144137499)x1 was detected in sample 24P. The size of the 
mutation is 200kb (figure 43) and the mean value is 0.205. Of the genes involved in this 
mutation the BAI1 and PSCA are of greatest interest. UCSC genome browser document that 
BAI1 encode for a brain- specific angiogenesis inhibitor 1. PSCA encodes a 
glycosylphosphatidylinositol-anchored cell membrane glycoprotein which is highly expressed 
in prostate in addition to the bladder, placenta, colon, kidney and stomach.  In many cases of 
prostate cancer this gene is up-regulated, and is also detected in bladder and pancreas cancers.  
 
 
Figur 43: Documentation of the results in the USCS linked following the bioinformatics analysis for sample 24P 
on chromosome 8. The detected CNVs position is marked in red on the illustrated chromosome. The genes 
involved are presented below in blue writing. The size of the mutation are presented in black above the genes 
and are in this case 200 kb in size.  
 
 
Figure 44: Fluorescence ratio profile over the CNVs detected for chromosome 8 on subarray A08 with the 
514596 array. To the left (y axis) the log2 ratio is presented, and on the bottom line the genome position is 




3.5.4 Results from analysis of parallels 
Parallels within one array and between arrays were analyzed to examine the methods 
reproducibility based on the hybridization problems with Cy5. 
 
Parallels of one sample analyzed on two different arrays. 
Sample 9P was analyzed on array number 509338 and 514596 and the results from these 
analyses are documented in table number 44 and 45. In these tables the green colour for the 
mean values columns documents that the detected CNVs are duplications and the red colour  
represent deletions. CNVs detected in both arrays are marked with an underline. 
 
Table 44: Summary of the results from bioinformatic analysis on patient sample 9P applied on the A05 subarray 





Probes Genes Mean DGV 
10q26.3 132014999 13240499
9 
8  0.5 No 
14q11.1-q11.2 
Centromere 
183949999 19304999 10  0.34 No 
21q11.2-22.3 1345499 46853544 465 The whole q arm is duplicated. 0.44 No 




Table 45: Summary of the results from bioinformatic analysis on patient sample 9P applied on the A02 subarray 





Probes Genes Mean DGV 
9p11.2 44167499 45207499 12 KGFLP1, AK126080, 






46182499 46702499 7 LOC554249, KGFLP1, 
AK126080, LOC643648 
0.21 No 
10q26.3 132047499 132437499 7 No genes found 0.401 No 
14q11.1-11.2 
centromere 










41827499 42152499 6 ARL17, LRRC37A2, ARL17PI, 
NSF, 
-0, 515 No 






Parallels of two samples run twice on the same array 
Sample 12P and 21P were analyzed in duplex on array 514596 to measure the methods 
reproducibility within one analysis, (tables 46-49). The green colour for the mean value 
columns represents duplications and the red colour deletions. CNVs detected in both parallels 
of the samples are marked with an underline. 
 
Table 46: Summary of the results from bioinformatic analysis on patient sample 12P applied on the A03 





Probes Genes Mean DGV 







8q11.21 48717499 48977499 5 KIAA0146, CEBPD, 



















10q11.22 46117499 46832499 12 BMS1P5, CR604707, SYT15 












A26B1, M84131, BC047459, 
DQ786202,IGH, OR4N4, 
DQ786202, AK058056, 
BC062994,  ORAM2 
0.231 No 














Table 47: Summary of the results from bioinformatic analysis on patient sample 12P applied on the A04 





Probes Genes Mean DGV 







15q11.2 18427499 19987499 14 LOC6446096, 
HERC2P3,GOLGA6L6, 
GOLGA8E, NBEAP1, POTEB, 
LOC646214, CXADRP2, 
LOC348120, NFIP2, LOC727924, 
ORAM2, OR4N4, OR4N3P, 
AX748135, A26B1, DQ595648, 




Table 48: Summary of the results from bioinformatic analysis on patient sample 21P applied on the A05 





Probes Genes Mean DGV 





41697499 42997499 13 MGC221881, KGFLP2, 
ANKRD20A2,  ANKRD20A3, 
FOXD4L2, FOXD4L4, AQP7P3, 
KGFLP2, DQ588135, 
DQ587539, AK125850, 





























18427499 19077499 7  0.331 No 
17q21.31-
q21.32 
41762499 42152499 7 LOC51326, LRRC37A,ARL17P1, 







Table 49: Summary of the results from bioinformatic analysis on patient sample 21P applied on the A06 





Probes Genes Mean DGV 











3.5.5 Comparison of the 3x720K and 12X135K array formats 
The summary table in appendix B (page XXI-XXIV) presents all the documented deletions 
and duplications found on array numbers 461678, 509338 and 514596 and compares the 













4.1 Gradient PCR 
Gradient PCR was performed on all primers used in PCR and sequencing experiments 
performed on the laeverin gene, to find the best annealing temperatures. By the use of only 
two PCR programs for all the primer sets the PCR experiments were more time efficient. As a 
consequence some of the primers were utilized at PCR programs without the best suited 
annealing temperature. However to be sure of correct analysis all PCR experiments were 
performed at annealing temperatures where the gradient PCR had documented production of 
distinct bands at the same size as the specific product of the primers. After thorough 
evaluation of the gel pictures from all gel electrophoresis analysis (figures 9-20), two PCR 
programs were designed. PCR program 1 had 57.8°C as annealing temperature and PCR 
program 2 had 65.4°C. Most of the primers produced specific bands at 57.8°C and were 
therefore applied in program 1 (table 39) while five of the primers were most suited for 
program two. For some of the primers unspecific bands were present at some or all 
temperatures. To avoid these, annealing temperatures where the unspecific bands were 
undetected were preferred. In some cases it was impossible to avoid unspecific bands because 
they either were present at all temperatures or were absent at the annealing temperatures 
utilized in program 1 and 2. None of the unspecific bands were so strong that they were 
considered to influence on the PCR product formed and the subsequent sequencing analysis. 
4.2 Sequencing of DNA from maternal blood samples 
The sequence variants detected in the sequencing analysis on DNA from maternal blood 
samples were documented in table 40.  The variants found in exon 7 (figure 22) and 10 (figure 
23) were the only variants detected exclusively in preeclampsia patients in translated exons.  
Further investigations detected presence of the variant in exon 10 in several normal controls 
and it was therefore ruled out as a possible pathogenic mutation.  The variant in exon 7 was 
not detected in any normal controls and may therefore be a pathogenic mutation which should 
be further investigated. In this variant one Glutamic acid in position 487 of the laeverin 
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protein is replaced with Lysine and both are hydrophilic amino acids. To investigate the effect 
of this variant, site directed mutagenesis may be performed.  Recombinants containing the 
variant in exon 7 could be constructed and their proteins enzyme activity may be compared to 
the enzyme activity of the wild type protein. Maruyama et al (2009) performed this type of 
study on one variant found in amino acid 379 in the laeverin gene (62).  
 
4.3 Sequencing of DNA from placental tissue  
Sample 15P collected from placental tissue was sequenced for all the exons in the laeverin 
gene and parts of the introns. The sequence variant detected in exon 6 was the only one of the 
variants that was not present in maternal blood for translated exons (table 41). In this variant 
the amino acid Lysine is replaced with Arginine. Both are hydrophilic amino acids. 
 
In the endoplasmatic reticulum and the Golgi apparatus O-glycosylation of Lysine residues is 
used to mark some proteins for secretion from the cells (63). Replacement of Lysine with 
Arginine may result in a deficient marking of the protein and thus no secretion of the protein 
from the cells. Immune fluorescence studies performed by Nystad et al on placental tissue 
sections from the preeclamptic women revealed that laeverin is localized to the cytoplasm in 
preeclampsia patients and in the cell membrane in normal controls. This could be due to this 
variant. However, this variant was only present in one of the strands (figure 25). The placental 
tissue samples used for sequencing were collected taking care to avoid contamination with 
maternal blood. Therefore despite a theoretical possibility it is unlikely that one strand could 
have been sequenced on maternal DNA and the other one fetal DNA. 
 
 The gene sequence of the placental sample from the preeclamptic patient was compared with 
the gene sequences of blood samples from normal and preeclamptic women, but not with the 
gene sequence of normal placenta, maternal decidua or the fetal blood. Therefore, we do not 
know whether similar variant can be present in the normal placenta, maternal decidua or the 
fetal blood. The variant was not detected in maternal blood from the same preeclamptic 
patient that the placenta sample was collected from. For further investigations several samples 
from placental tissue from preeclamptic patients and normal controls should be screened for 
this variant. If it is detected in several samples from preeclamptic patients and not in any 
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normal controls this could be an indication of a potential pathogenic mutation. If the variant is 
not detected in any normal controls or more preeclamptic samples it may be a familial variant. 
 
 
4.4 Evaluation of scanned arrays 
Array number 461641 
All three subarrays have an uneven distribution of Cy5 (figure 26). Some positions on the 
subarrays have distinct red gradients because more of the Cy5 has hybridized to the probes 
than to the other positions. The Cy3 is evenly distributed for all subarrays. Due to the poor 
hybridization of Cy5, the signal intensity for the labelled DNA with this dye was too low 
for obtaining correct results.  
 
Array number 461678 
The same DNA mixture as the one analyzed with array number 461641 were re-analyzed 
with array number 461678 with a new labelling kit. The data analyses of 461678 shows 
some variation between the A01, A02 and A03 parallels and are presented in appendix A 
(page I-IV). Ideally the three subarrays should show exactly the same regions duplicated 
and deleted since they contain the same sample material.  A03 has a more uneven 
distribution of Cy5 than A01 and A02 (figure 27). At the bottom right corner there are some 
light green artefacts present and to the left some black artefacts. A01 and A02 have an even 
distribution of the two colours.  
 
Array number 461424 
Array 461424 has some of the same problems as 461641 regarding hybridization of Cy5 
(figure 28). The signal intensity of Cy5 was too low for obtaining correct results and the 
analysis was excluded. 
  
 Array number 509338 
All subarrays except for one have an even distribution pattern of Cy3 and Cy5 (figure 29). 
Subarray A10 contains one large air bubble and A11 and A12 have some black artefacts 
present. According to the protocol from NimbleGen these black marks could be washing 
artefacts. The Cy5 and Cy3 may have been damaged by the components in the washings 
84 
 
solutions in these areas. Since this array has an even distribution of Cy5 further analyses 
were performed on this array, and are presented in appendix A (page IV-IX). 
  
Array number 514596 
The distribution pattern of Cy5 varies between the different subarrays.  A12-A09 have 
many clear green areas where the red colour is absent. The results from data analyses of 
these subarrays are presented in appendix A (page XIV-XX). The A12- A09 subarrays have 
a much higher number of duplications present compared to the others subarrays and arrays.  
Large parts of these four subarrays are mostly green, and seem to lack hybridization of Cy5 
(figure 30). The normal controls were labelled with Cy5 and when these are absent due to 
poor hybridization the patient`s genome will be presented with a large amount of 
duplications and the results will be erroneous.  
 
Hybridization problems 
Poor hybridization of Cy5 was a problem for several of the arrays presented above. Cy3 and 
Cy5 were handled in the same way and in accordance to the protocol in all steps in the 
aCGH analysis. The hybridization reaction is sensitive to several conditions such as, salt 
concentrations, temperature, mixing of samples prior to loading, amount of labelled DNA 
and the duration of the hybridization reaction. High salt concentration improves the labelled 
DNAs ability to hybridize to the probes on the array. Temperatures influence on the 
stringency of hybridization, and high temperatures in the hybridization reaction and 
washing steps makes the hybridization reaction more stringent and reduce the amount of 
unspecific binding. Cy3 and Cy5 were handled under the same salt and temperature 
conditions and the same quantity of DNA labelled with Cy5 and Cy3 were combined before 
hybridization. Therefore both colours should have been evenly distributed. Before 
application on the arrays the patients samples were combined with normal controls and 
mixed and vortexed thoroughly.  Cy5 was only present at some locations on the arrays and 
may indicate that it was more viscous than Cy3. However according to the manufactures 
both colours have the same viscosity. There could be some problems with the Cy5 
fluorochrome but it doesn’t explain why it is present in large quantities in some areas and 
are absent from others. If the flurochrome weren’t properly attached to the nucleotide, Cy5 
should be absent from all locations and not present in large quantities in some positions. 
aCGH is sensitive to DNA quality. After labelling all samples were quantified with 
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NanoDrop, and all samples had high concentration of labelled DNA, therefore the sample 
quality is not a reasonable explanation to the poor hybridization. The high quantity of the 
labelled DNA also rules out low fluorescence intensity from Cy5 as a possibility. In 
addition some parts of the subarrays have strong red signals indicating that the intensity 
from the fluorochrome is good enough. The problem could be due to poor mixing of the 
solutions in the hybridization instrument. However if the problem were poor mixture of the 
solutions during hybridization there should be an uneven distribution of both Cy3 and Cy5 
and not only Cy5. The hybridization reaction was performed within the range of the 
recommended time.  
 
4.5  Interesting findings 
The most interesting findings from the aCGH analysis were presented in section 3.5.3 (page 
69-76)  
 
CNV 17q 21.31-q21.32.  
The copy number variant arr17q21.31q.21.32(41599999-42119999)x1 was detected in the 
fetal genome of one preeclampsia patient while  arr17q21.31q.21.32(41599999-42119999)x3 
was documented in several. The fetal genome is closely related to placental genome and can 
influence maternal physiology through a variety of biological mechanisms. Previous research 
by Nystad et al documented that the transportation of laeverin protein from the Golgi 
apparatus to the cell membrane may not be functioning properly in preeclamptic placentas 
(un-published observations). From these experiments it is not clear whether laeverin is 
retained in the Golgi apparatus or if it is localised in other cell compartments. To clarify 
whether laverin is retained in the Golgi apparatus in preeclamptic placentas electron 
microscopic experiments needs to be performed. NSF is involved in transportation within the 
Golgi apparatus and it is therefore possible that there are some interacting effects between 
laeverin and NSF. If NSF is required for transportation of laeverin from the Golgi apparatus to 
the cell membrane this might explain the depletion of laeverin in the cell membrane. 
Reduction of the amount of the protein encoded by NSF due to deletions of the NSF gene may 
result in retention of laeverin. NSF was deleted in one preeclampsia patient and duplicated in 
several patients. Duplications and deletions may alter the protein`s structure and thereby its 
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function. If the protein function is altered then its transportation capacity may be reduced 





The CNV arr 7q11.23(72019999-72409999)x1 was present in the fetal genome of one 
preeclamptic patient while the variant arr 7q11.23(72019999-72409999)x3 was documented 
in several. The orthologous gene to FKBP36 in mouse is essential in fertility and homologous 
pairing in male meiosis and FKBP36 may therefore be involved in fertility in humans. 
Documentation of high expression levels in the testis in human males is an indication for this. 
It’s belonging to the immunophilin protein family which are involved in immunoregulation 
and basic cellular processes such as protein folding and trafficking makes it even more 
interesting. Contribution of the immune system in development of preeclampsia has been 
indicated in several studies. As for NSF its role in trafficking may be linked to depletion of 
laeverin in the cell membrane. Its function in protein folding is also interesting since incorrect 
folded proteins are not transported from the Golgi apparatus. FKBP36 was only deleted in the 
umbilical cord blood sample from the newborn of a preeclamptic mother. Deletion of this 
gene might be a familial variant. Another possibility could be that both deletions and 




The CNV arr15q11.1-q11.2(18394999-21059999)x1 was deleted in several umbilical cord 
blood samples from the neonates of preeclamptic patients. Expression of POTEB in prostate, 
ovaries and testis implies for involvement of this gene in fertility, and it may therefore be 
involved in processes leading to preeclampsia. POTEB belongs to the ankyrin family which is 
involved in the maintenance of cell membranes. Ankyrins are important for the correct 
localization of the ion channels in the cell membranes (61). Since the deletion is detected in 
several neonates of preeclamptic patients the protein product may be reduced resulting in 
malformations of cell membranes in important cells in the placenta development. If this gene 
is involved in maintenance of cell membranes in extravillous trophoblast the deletion may 
alter their cell membranes resulting in poor placentation. However, so far ankyrin has not 
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been characterized in extravillous trophoblast or other cells involved in the placental 
development. This should therefore be further investigated.  
 
GOLGA8E is highly expressed in testis and encodes for a Golgi autoantigen. Since it is 





The CNV arr19q13.31(48162499-48299999)x1 involved genes that encodes for human 
pregnancy-specific glycoproteins (PSGS) secreted by the syncytiotrophoblasts. 
Syncytiotrophoblasts participate in the formation of the villus tree and are therefore essential 
for the utero placental circulatory system and formation of the placenta. The influence of the 
(PSGS) proteins in placental development should therefore be examined.  One possibility is 
that a reduced amount of these glycoproteins may induce alterations which lead to 
development of preeclampsia. If these proteins are necessary for differentiation or formation 
of syncytiotrophoblasts a reduced amount may lead to malformation and poor development of 
the placenta. The maternal symptoms in preeclampsia are believed to be induced by factors 
released from the hypoxic placenta. If these pregnancy-specific glycoproteins are essential for 
the development of syncytiotrophoblasts then a reduced amount could lead to malformation of 
the placenta which in turn releases factors into the circulation and the maternal symptoms 
develops. In addition, these genes and their products involvement in the immune system is an 




The CNV arr1q31.3(19486999-1951299999)x1 was detected in one umbilical cord blood 
sample from the neonate of one preeclamptic patient and involves several genes associated 
with the complement system. The CFHR1 gene encodes for a protein belonging to the 
complement factor H protein family and may be involved in control of complement and tissue 
invasion. Since the development of the placenta and establishment of the utero placental 
circulatory system is dependent on invasive EVTs, deletions of this gene may have negative 
influence on the EVT invasion. CFHR1 is highly expressed in several organs including the 
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fetal liver. Fetal genes may contribute to the development of preeclampsia and these findings 
are therefore interesting. The other genes represented in this deletion (figure 41) are also 
associated with complement system and may have some functions related to EVT invasions. 





CNV arr8q24.3(143552499-144137499)x3 contains one gene that encodes a brain-specific 
angiogenesis inhibitor. Preeclampsia is characterized by poor development of the early 
placenta and the maternal blood supply and angiogenesis inhibitors may therefore be 
involved.  Duplications of BAI1 could cause an overproduction of the angiogenesis inhibitor, 
resulting in reduced remodelling of the spiral arteries and thereby poor placentation. Tumor 
cells are dependent on angiogenesis for their growth and metastasis. Increased secretion of 
angiogenesis inducers and decreased production of inhibitors promotes angiogenesis. The 
protein encoded for by PSCA is also involved in cancer and is expressed in the placenta. 




4.6 Evaluation of the analyzed parallels 
Between runs 
For sample 9P the cytobands 10q26.3, 14q11.1-q11.2, 21q11.2-q22.3 and 17q21.31-q21.32 
were present on both arrays (table 44 and 45).  In addition 9P analyzed on 514596 has 
detected the cytobands, 9p11.2, and 9p11.2-11.1.  The chromosomal position 21q11.2-q22.3 
involves trisomy 21 and is detected in both analyses. Since both aCGH analysis detects 
almost the same findings and taken into consideration that this is a screening method where 
findings should be verified by a second independent method, the reproducibility between 
runs are considered to be good enough. In addition the detected trisomy 21 has been 
verified by G-banding performed by the staff at the Divison of Child and Adolescent 






The bioinformatical analysis of parallels of the samples 12P and 21P have varying results. 
(tables 46-49). Only some cytobands are present in both parallels. For sample 12P the 
Cytobands 10q11.22 and 15q11.2 are found in both parallels (tables 46 and 47). Cytobands 
7q11.23,8q11.21,9q13.1-q13 are found in only the first parallel analyzed on subarray A03 
not in the one analyzed on A04. The Cytobands 17q21.31-q21.32 is the only one in 
common for both parallels for sample 21P (tables 48 and 49). Cytoband 9p13.1-p12, 
9p11.2, 9p11.2-q12, 9q12 and 14q11.1 are all detected in only one of the parallels. 
 
The scanned images of A03-A06 (figure 30) which represents these samples seem to have 
an even distribution of both Cy3 and Cy5 for most parts of the arrays. A05 and A03 have 
both a distinct red gradient at the right side of the subarrays. Probes located in these areas 
could give false results and may to some extent contribute to the variation. However probes 
for the different genes are placed at several areas on the arrays and the red gradient is only 
present at the right side of the subarrays, and does not explain the degree of variation. 
 
The variation between the parallels within one analysis is quite large, and ideally it should 
be lower. However, aCGH is a screening method and the results should always be verified 
by a second independent method. If the copy number variants detected by the aCGH 
analyses are confirmed by a second independent method then they are considered to be 
reliable. 
 
4.7 Comparison of findings on the 3X720K and 12X135K arrays. 
The 3x720K arrays were used as a pre-screening to investigate if some of the preeclampsia 
samples contained genes which could be involved in preeclampsia and to examine if it was 
possible to analyze mixtures of samples on one subarray. The summary table in appendix B 
(page XXI-XXIV) presents all variants detected for all arrays and documents the variation 
between the different arrays. Several of the CNVs detected by the 12X135K arrays are not 
represented in the 3X720K arrays and vice versa. The variation between the 12X135K arrays 
and the 3X720K arrays might be explained by resolution and sample material. The 3X720K 
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array format has a higher resolution than the 12X135K arrays and when single samples are 
run more CNVs should be detected with these arrays. However when a pool of 19 samples 
was analyzed the amount of DNA from each sample was much smaller than when one single 
sample was analyzed with the 12X135K arrays. Some CNVs might therefore be undetected.  
Therefore some of the copy number variants present on the 12X135K arrays might be 
undetected on the 3X720K arrays. In addition a large amount of the variants detected in the 
12X135K arrays are duplications in array number 514596. As presented earlier the Cy5 had 
an uneven distribution for many of the subarrays, resulting in detection of many duplications. 
It is therefore likely that many of these findings are not real aberrations, and they should be 
evaluated by a second method. The fact that some of the copy number variations are 
documented in both array formats demonstrates that pooling of samples was possible. 
 
 
4.8 Further investigations 
All detected copy number variations should be verified by a second independent method. 
Most of the detected CNVs were too small to be detected by traditional G-banding. 
However FISH and qPCR are well suited methods for confirmation. In addition to copy 
number variation FISH analysis detects inversions and translocation that are undetected by 
aCGH or qPCR. FISH analysis is a more time consuming method compared to qPCR, 
where several samples could be analyzed in one run. If the copy number variations are 
confirmed, further investigations regarding their contribution to preeclampsia ought to be 
performed.  
 
To investigate if the genes presented in section 3.5.3 (page 69-76) may contribute to 
preeclampsia gene expression profiles from fetal DNA should be performed and compared 
to gene expression profiles from fetal DNA from normal pregnancies. Western blot may 
also be used to analyze proteins encoded by these genes in preeclampsia patients. 
Experiments with antibodies directed against the proteins in question may be used to detect 
their distribution pattern in the cells and to gain insight into the amount of produced 
proteins. To investigate if the genes are essential in placental development, cell culture 
experiments where these genes are knocked-out by siRNA may be used. The methods 
presented above should be performed on a large number of preeclamptic patients to 
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investigate if there might be a common link between them or if some of the CNVs could be 
a familial variants.  
 
NSF and FKBP36 may be involved in transportation of laeverin to the cell membrane and 
the samples used in the immunofluorescense study performed by Nystad et al ought to be 
investigated for deletion or duplications of these genes to investigate if there is a link 
between these findings. Deletions of FKBP36 and NSF could result in depletion of the 
protein products and thereby result in too few proteins for transportations. Duplications and 
deletions may alter protein structure and function, and in this way produce abnormal 
proteins.   
 
All documented CNVs contain more than one gene and there might be interacting effects 
between them which should be taken into consideration in the interpretation of results. In 
addition many of the genes are presented with unknown functions and some of these may be 





Two detected variants in the laeverin gene were found exclusively in preeclamptic patients in 
the sequencing analysis. The effect of these variants on enzyme activity should be examined.  
The variant detected in exon 6 is of special interest since Lysine is replaced with Arginine.   
O-glycosylation of Lysine residues marks some proteins for secretion from the cells. 
Replacement of Lysine may therefore result in retention of laeverin in the Golgi apparatus 
and may explain the depletion of laverin in the cell membrane of throphoblasts in 
preeclampsia patients.  
 
The aCGH analysis revealed copy number variations for genes involved in vesicle transport, 
protein folding, maintenance of cell membranes, production of pregnancy-specific 
glycoproteins, immunological reactions, complement system, tissue invasion, angiogenesis 
inhibitors and cancer. The ability of aCGH to screen the whole genome in one single test 
makes it less time consuming and provides a large amount of information compared to other 
traditional methods. Using this method we detected several genes which may be linked to the 
pathogenesis of preeclampsia. However these findings should be confirmed by a second 
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In this appendix all detected CNVs by aCGH are presented with their chromosome position, 
start and end positions for the probes, number of probes involved in the variant, mean values, 
genes and if they are documented in DGV. 
 








Probes Genes Mean DGV 
4q22.3  
 




72087499 72349999 20 GTF2IRD2P, FKBP36 
STAG3L2, GTF2IPI, 
GTF2IRD2B,  NCF1C, 











101849999 102062499 15 PRKRIP1, ALKBH4, RASA4, 





8p23.3 0 74999 7 BC071667 -0,57 No 






31812499 33712499 78 TP53TG3,  ZNF267, IGHV, 





BC041879, SLC6A8, Z14218 
 -0.22 No 
 
19q13.31 48162499 48299999 5 PSG2,PSG11,PSG6  -0.24 No  
22q11.21 
 
17012499 17224999 10 AK129567,GGT2, POM121-
like 1, DKFZp434K191, 
USP18, AK748067, 
-0.39 No  
22q11.21 18787499 19024999 9 LOC375133, AK129567, 
RIMBP3, 
-0.38 No  

















Probes Genes Mean DGV 
1p36.33 24999 787499 24 AK311604,  DQ580039, 
AK026901,  X64709, 
LOC643837, OR4F16 
-0.28 No 
1p36.13 16749999 16962499 7 NBPF10, NBPF1, FLJ00313, 
MST1,  AL035288, KIAA0445,  
MSTP9, 
 -0. 23 No  
 
4q28.3 131337499 131449999 9  0.2 No  
7q11.23 
 
72062499 72337499 22 FKBP36, STAG3L3, 
PMSL214,  LOC441259,  
GTF2IPI,  NCF1C, 
GTF2IRD2B,  NSUN5C, 





73774999 74949999 71 GTF2I,GTF2IRD2, STAG3L2, 
PMSL25, AK095583,  






GTF2IP1, hPMS7, BC110795, 
PMS2L14, DQ579684, 
AK095583,  AL832384, 
WBSCR16,  AL831977, 




POM121C,  POM121-2, 
-0.24 No 
7q22.1 99662499 99762499 10 STAG30S, SPDYE3, 
PMS2L13 
-0.25 No  
7q22.1 
 
101849999 102099999 17 PRKRIP1, ORA12, LRWD1, 
POLR2J, KIAA0538, UPLP, 
RASA4, AK31174, BC085014, 
ALKBH4, DQ601342,  
SPDYE2, 
-0.37 No 
8p23.3 0 7499 7  -0.54 No 
9p21.1 31274999 31349999 6  0.2 No  
11p15.5 62499 224999 7 IFITM5, DQ584937, 
AK310751,  BX647595, 
DQ577244,  SCGB1C1, 




26049999 26812499 29 HERC2, FLJ36131, 







31862499 33712499 75 TP53TG3b, HERC2P4, IGHV, 
IGH, I GHV3-30, X69637,  
BC041879, DQ571479,  
TP53TG3, LOC440366, 
DQ574674, BC038215,  
SLC6A10P, BC038215, 








Probes Genes Mean DGV 
21p11.2-q11.2 
Centromer 
9887499 13512499 13  -0.26 No  
22q11.21 
 
17074999 17224999 7 GGT2,  POM121-1 like, 
AK129567,  DKFZp434K191, 
AX748067, 
-0.21 No  
22q11.21 18762499 19024999 11 LOC375133, AK129567, 
RIMBP3 
-0.28 No  
22q11.21 
 
19824999 20237499 23 AK129567, GGT2, BC039313, 
DKFZp434K191, PI4KAP2, 
AK094490, AK128832,  
BC053652, BC112340, 
DQ571494, BCR, RIMBP3B,  












Probes Genes Mean DGV 




AK311374,  HSPC047, 




0 49999 6 BC071667 -0.59 No 
15q11.2 
 
18412499 20274999 82 HERC2P3,  POTEB, 
GOLA8E, OR4N4, 
OR4M2,  DQ576041, 
LOC642311,  DQ592463, 
AX748135, DQ582073, 
DQ595648, DQ592322, 
AL832227,  DQ582260,  
POTEB,  A26B1,  M84131,  
BC047459, DQ786202,  
AK058056,  BC062994,  
OR4N4,  OR4M2,  
LOC650137, CR619482,  
OR4N4, DQ582025,  
DQ582940,  DQ599733 







Probes Genes Mean DGV 
15q13.1 26112499 26824999 25 HERC2,  FLJ36131, 
GOLGA8G, DQ579249, 
AK095014, DQ592322, 





DQ582025,  DQ582940, 
DQ597560,  BC150525, 
BC150524,  BC066982, 
AK091254,  BC035099, 
AK311660 
-0.24 NO 




-0.44 No  
22q11.21 18774999 19024999 10 LOC375133,  RIMBP3, 
AK129567 
-0.36 No 
22q11.21 19924999 19987499 5 BC112340,  DQ571494, 




 Array number 509388 





 probes Genes Mean DGV 
8p23.1 6824999 7799999 9 AK0307331,  SPAG11B, 
DEFB10,  HE2,  LOC728358, 
AF355799, DEFA3, DEFA5, 
BC030294,  AK307331, 
DEFB109,  DEFB4,  HE2, 
DEFB103B,  DEFB104A, 
DEFB106A,  DEFB105A, 
DEFB107B,  SPAG11A, 
DEFB103A 
-0.42 No 
15 q11.1-11.2  18394999 20214999 16 HERC2P3,  AX748135, 
DQ58226,  DQ582073, 
GOLGA8E, DQ592322, 
DQ578838,  POTEB, M84131, 
BC047459,  OR4N4, IGH, 
OR4M2,  CR619482,  DQ786202 
-0.31 No 
16p11.2 28274999 28599999 6 EIF3C, CLN3, APOB48R, 





32564999 33474999 8 TP53TG3, TP53TG3b, 
DQ574674, BC038215, 
LOC440366, SLC6A10P, IGHV, 




41599999 42119999 10 KIAA1267, ARL17, LOC51326, 











Probes Genes Mean DGV 
4q12-31.1 58304999 64024999 76 LEC3,  LPHN3,  BC039452, 0.21 No 
7q11.22-q11.23 
 
71629999 76439999 73 SBDSP, NSUN5, POM121, 
STAG3L3, TRIM74, PMS2L14, 
SPDYE8P, STX1A,MLXIPL, 
WBSCR22-27-28, RFC2, PMS2L5, 
STAG3L2, GTF2IPI,DTX2, STYXL1, 
around 100 genes in total. 
-0.25 No 
7q.22.1 99969999 102244999 33 AGFG2, PP1483, FLJ00248, 
LRCH4, MOSPD3, TFR2, 
GNB2,EMID2,  ZAN,  PLOD3, 
CUX1,PRKRIP1, KIAA, +++++    
around 80 genes 
-0.29 No 
9p13.1-q13 39129999 70134999 125 CTNAP3, KIAA1714, FAM75A2, 
ZNF658B, KGFLP, ANKRD20A3, 
AK126080, CR605783, FAM75A7, 
LOC554249, FOXD4L5+++++ 




58174999 60124999 26 ZNF,VNIR2-4, KIAA, NALP12, 
PRKCG, MYADM, CACNG7, 
PRPF31, FLJ,LAIR1, KIR2DL3, 
LILRA4, +++ around 80 genes 
-0.23 No 
 





Probes Genes Mean DGV 
8p23.1 6824999 7864999 9 DEFB10, SPAG11B, SPAG11A, 
ZNF705D, HE2, AK307331, 
LOC728358, AF35579, DEFA3, 
BC030294,  AK307331, DEFB109, 








38999999 41859999 41 CNTNAP3, KIAA1714, 
DKFZ572C163, ZNF658B, 
FAM75A2,  LOC401507, 






43224999 67339999 62 AK054645, DQ586551, 
DQFZp686115204, DQ579969, 




BC068605, AQP7P1, MGC21881, 
DQ597175, AK131029, DQ594428,  
AL953854.2-002, LOC643648, 
AK308561 ,BC01179, CR627148, 
BC068605, LOC442421, 
AK309896, AK000451, MGC2881, 
BC019880, BC065763, AK310876, 
AK074198, BC070322, BC071803, 








Probes Genes Mean DGV 
14q11.1-11.2 
Centromer 
18394999 19109999 9  -0.27 No 
15q11.1-11.2 
 
18394999 19954999 15 DQ576041, CR622584, DQ592463, 
HERC2P3,  AX748135, DQ582073, 
GOLGA8E,D Q578838, 
DQ582025, A26B1,M84131, 
BC047459, POTEB, ORAM2, 
AK058056 
0.26 No 













Probes Genes Mean DGV 
3p26.2 4159999 4354999 5 SUMF1,  SETMAR -0.65 No 
6q27  168089999 168284999 5 MLLT4,  HGC6.1.1, KIF25, 
FRMD1, AK289488,  FLJ00181 
0.37 No 
9p21.2 25609999 25869999 5 TUSC1, BC043546, -0.27 No 
17q21.31-21.32 41729999 42119999 8 ARL17P1, LOC51326, LRRC37A, 
LRRC37A2, NSF,  ARL17 
-0.51 No 
 





 probes Genes Mean DGV 
10q26.3 132014999 132404999 8  0.5 No 
14q11.1-q11.2 
Centromer 
183949999 19304999 10  0.34 No 
21q11.2-22.3 1345499 46853544 465 The whole q arm is duplicated. 0.44 No 









Probes Genes Mean DGV 
8p23.1 7214999 7864999 8 DEFB4, SPAG11B,SPAG11A, 
DEFB10103-104-105-106A, 




50894999 51284999 6 PARG, AGAP8, CTGLF1, 
DQ588223, TIMM23, AK098044,  
AGAP7, DQ588224, MSMB,  
NCOA4, 
0.24 No 
13q21.31 62009999 62594999 8   0.25 No 
VII 
 
15q11.1-q11.2 18394999 19954999 15 DQ576041, DQ592463, 
HERC2P3, AX748135, 
DQ582073, DQ595648, 
GOLGA8E, DQ592322,  POTEB, 
DQ582073, AL832227, A26B1, 
M84131, BC047459, DQ786202, 
OR4N4, OR4M2, AJ004954, 
LOC650137,  LOC642311, 
DQ576041, DQ592463, 
DQ578838, DQ582025,D 
Q582260, CR619482, AK058056 
-0.42 No 
 





Probes Genes Mean DGV 





1p36.13 16769999 17159999 8 NBPF10, FLJ00313, MST1, 
AL035288, MSTP9, KIAA0445, 
CROCC 
-0.24 No 
9q12 65454999 65779999 6  -0.23 No 
10q11.22 
 
46149999 46799999 12 BMS1P5, CR604707, SYT15, 
GPRIN2PPYR1, ANXA8L1, 
LOC643650,  BC075841 
0.33 No 
 





Probes Genes Mean DGV 
16p11.2 
 
31914999 33474999 14 TP53TG3B, HERC2P4,  IG VH, 
IGHV3-30, IGH, X69637, 
BC042588, BC041879, 
DQ571479, TP53TG3, 
LOC440366,  DQ574674, 





18654999 19077499 9 DGCR6L, AK129567, GGT2, 
AX747971 ,AK094309, 









Probes Genes Mean DGV 
14q11.1-11.2 
centromer 
18394999 19304999 10 POTEG, A26C2, AY458019, 
AK056135, DQ595091, DQ591735 







18394999 21059999 25 HERC2P3,  DQ592463, POTEB, 
A26B1,  M84131, OR4N4, 
GOLGA8E, TUBGCP5, AJ004954, 
NIPA2, WHAMML1, KIAA0393, 
DQ576041, CR622584,BC012949, 
AX748135, DQ582073,  DQ595648, 
DQ592322, DQ578838, DQ582025 
,AL832227, DQ582260,  BC047459, 
DQ786202, AK058056, 
BC06,OR4N4, ORAM2, LOC650137, 
CR619482,  AJ004954,  DQ582025, 
DQ582940, DQ599733, LOC283767, 
DQ582071, TUBGCP5, KIAA1899, 
CYFIP1, NIPA2, BC044583, 
WHAMML1,  DQ583692, 
DQ572986,  AX747926, DQ600343, 





41729999 42119999 8 LOC51326 ,LRRC37A, LRRC37A2, 
ARL17P1, ARL17, NSF, 
-0.61 No 
22.q11.23 3 23919999 24179999 5 KIAA1671, CRYBB3,CRYBB2 
BC040576, LRP55L , BC047380, 
BC037884,  IGLL3 
0.27 No 
 
Subarray A10 Sample number 16P 
No deletions or duplications were detected for this subarray. 
Position Start position End position Number of 
probes 
Genes Mean 
      
 





Probes Genes Mean DGV 
1q31.3 
middle 






68834999 70654999 22 OCLN, LOC730394, GTF2H2D, 
AX748379,  DQ570149, SMA4-
5,SMN2, NAIP, AK311046, S74729, 
BC045789, SERF1B, DQ570081,  
AK311627, DQ571461,  
DQ575504, DQ571494,  
AK124130, DQ587764,  SERF1, 
DQ575504, DQ570150,  
DQ596233, DQ591061,  
DQ786306, AF073520,  BC045789, 
DQ786263,  DQ587763, 
GTF2H2B, GUSBP1, LOC730394, 
AX748379,  SMA3, DQ596042, 
DQ573166, DQ587763, 
DQ570081, DQ599922, 





7q11.23 72019999 72409999 8 POM121, NSUN5C ,TRIM74, 
BC073780, LOC541473,STAG3L2, 
PMS2L14, SPDYE8P, FKBP36, 
GTF2IP1, hPMS7, WBSCR20C 
BC073780, BC022013, 
LOC541473, STAG3L2, STAG3L3, 
PMS2L14, hPMS7, BC110795, 
BC068610, NCF1C, GTF2IRD2B, 






73774999 74879999 16 GTF2I GTF2IRD2, PMS2L5, 
STAG3L2, WBSCR16, 
GTF2IP1,PMS2L14, SPDYE8P 
,NSUN5, TRIM73, BC068610, 
BC070376,TFII-I,NCF1, 
BC047594, BC110795, hPMS7, 
DQ579684, AK095583, AL832384, 
WBSCR16, NCF1C, BC068610, 








18394999 19304999 10  0.21 No 
15q13.1 2  26194999 26714999 5 HERC2, FLJ36131, GOLGA8G, 
FLJ32679, LOC283767, 
DQ592322, DQ57883B, 
DQ583954, FLJ32679, DQ579249, 
DQ599733, FLJ36131, DQ582071, 
AK309255, AK307870, AK095014, 
BC047911 
-0.31 No 
16p12.1 22359999 22554999 5 DQFZp547E087, LOC641298, 
LOC641298, LOC23117, 





41599999 42119999 9 KIAA1267, LOC644246, 
LOC51326, LRRC37A, LRRC37A2, 
ARL17P1, ARL17, NSF 
0.33 No 
 





Probes Genes Mean DGV 




21644999 21969999 7 TCRA, TCRAV8.1a, AV2S1A1, 
TRD, AV30S1, TCRAVN1, TCR-









Probes Genes Mean DGV 
15q11.1-q11.2 
 
18394999 19954999 15 HERC2P3,P OTEB  ,OR4N4, 
DQ576041, LOC642311, 
DQ592463, CR622584, 




DQ582260, A26B1, M84131, 
BC047459, DQ786202, 





Array number 514596 
 





Probes Genes Mean DGV 
5q13.2 6932249
9 
70622499 15 SMA4, SERF1, SERF1B, SMN2, 
AF073520, BC045789, NAIP 
GTF2H2B, GTF2H2, OCLN, 
AK311046, GUSBP1, SMA5, 




8p23.1 7182499 7897499 8 DEFB4, SPAG11B ,DEFB104A 















Probes Genes Mean DGV 
9p11.2 44167499 45207499 12 KGFLP1 , AK126080, 
CR615666,  DQ594366, 





46182499 46702499 7 LOC554249, KGFLP1, 
AK126080, LOC643648 
0.21 No 
10q26.3 132047499 132437499 7 No genes found 0.401 No 
14q11.1-11.2 
centromer 
18752499 19142499 6 BC016035, AK022914, 









41827499 42152499 6 ARL17, LRRC37A2, 
ARL17PI,NSF 
-0, 515 No 
XI 
 









Probes Genes Mean DGV 
7q11.23 74327499 74847499 6 BC068610,  BC047594, 















39292499 70167499 122 FAM75A2, DKFZp572C163 
ZNF658B, KGFLP2, FAM74A3, 
CTNAP3B, DKFZp686115204, 
LOC401507,CR933660,DQ588
135, DQ587539, CBWD5, 




10q11.22 46117499 46832499 12 BMS1P5, CR604707, SYT15 







15q11.2  18427499 20247499 15 DQ576041, CR622584, 
HERC2P3,AX748135,GOLGA8
E), POTEB, DQ582073, 
DQ595648, DQ578838, 
DQ582025, A26B1, M84131, 
BC047459, DQ786202, 
IGH,OR4N4, DQ786202, 
AK058056, BC062994, ORAM2 
0.231 No 
















Probes Genes Mean DGV 









15q11.2 18427499 19987499 14 LOC6446096, HERC2P3, 
GOLGA6L6,GOLGA8E,NBEAP1,
POTEB, LOC646214, CXADRP2, 
LOC348120, NFIP2, LOC727924, 
ORAM2, OR4N4, OR4N3P, 










Probes Genes Mean DGV 





41697499 42997499 13 MGC221881,  KGFLP2, 
ANKRD20A2, ANKRD20A3, 
FOXD4L2, FOXD4L4, AQP7P3, 
KGFLP2, DQ588135, 
DQ587539, AK125850, 


















9q12 66787499 68412499 12 BC070322, BC071803, AQP7P1, 
BC064331, FAM27E3, 
DQ786189,   BC110369, 
AK308561, ANKRD20A3, 
ANKRD20A1 BC110369, 




18427499 19077499 7  0.331 No 
17q21.31-
q21.32 
41762499 42152499 7 LOC51326, LRRC37A, ARL17P1, 









Probes Genes Mean DGV 



















Probes Genes Mean DGV 
1q21.1 143292499 143812499 6 NBPF1, NBPF10(NBPF family), 
NBPF20, NBPF14, CR603237, 
KIAA1245, NBPF8, COAS3, 
PDE4DIP, SEC22B, BX647792, 
AX747132 
0. 211 No 
1q21.1 147517499 147777499 5 FCGR1C, BC023516, 0. 232 No 
1q21.1 146542499 147192499 7 KIAA, NBPF1, NBPF12, 
KIAA1693, BC110832, NBPF14, 
NBPF10, NBPF20, NBPF16 




69062499 70687499 19 SMA4, SERF1, DQ575504, 
DQ570150, SERF1B, SMN2, 
GUSBP1, GTF2H2D, GTF2H2B, 
SMA5, DQ596233, DQ591061, 
AF073520, BC045789, 
DQ786306,S74729, NAIP, 






57557499 58402499 13  0.266 No 
7q11.21 
 





71662499 72442499 13 TYW1B,SBDSP, POM121, 
NSUN5C,TRIM74,  STAG3L2, 
LOC441259, PMS2L14, NCF1C 
GTF2IRD2B, TRIM50, 
BC047594, SPDYE8P, 







73807499 74977499 16 GTF2I, STAG3L2, TFII-1, 
NCF,GTF2IRD2, PMS2L5, 
BC047594, hPMS7, BC110795, 
GTF2IRD2B, BC068610, 
PMS2L14, WBSCR16, AL831977, 
DQ571357, DQ579684, 














40852499 70167499 100  0.307 No 
16p13.11 
middle 










Probes Genes Mean DGV 
16p11.2 
 




LOC606724, AK096982, MLAS 





21q11.2 13487499 13812499 6  0.29 No 
 
 





Probes Genes Mean DGV 
8q24.3 143552499 144137499 7 BAI1, ARC, JRK, C8orf55, LY6D 
LY6K, CR590598, PSCA, ,SLURP1, 
LY6uPAR GML ,LYNX1, CYP11B1, 
CYP11B2, H8 
0. 205 No 
9p13.1 39357499 40072499 12 ZNF658B , FAM75A2, 0.225 No 
9p12 40917499 41242499 5 No genes found 0.223 No 
9p11.2 42867499 43712499 13 BC052332,BC071803, ,DQ587119, 
BC064148, AK125850, ANKRD20A2, 
ANKRD20A3 DQ786189, 
AK054645,CCDC29, 





46182499 46702499 7  0.213 No 





16p11.2 31687499 33377499 15 ZNF720, FKSG41, ZNF267, IGHV, 
IGHV3-30, HERC2P4, TP53TG3b, 
BC041879, LOC440366, DQ574674, 
BC038215, SLC6A10P, IGHV, IGH, 










Probes Genes Mean DGV 
2p25.3 747499 1072499 6 BC043553, BC128532, CR592733, 
LOC391343,SNTG2  
0.518 No 
5q13.2 69062499 70817499 21 SMA4, SERF1, DQ575504, 
DQ570150,  DQ596233, DQ591061, 
ERF1B,SMN2, GUSBP1, GTF2H2D 
SMA5 ,BDP1, PMCHL2, 
OCLN,NAIP, LOC730394, S74729, 
AF073520, DQ571494, DQ571461, 




DQ786306, AK311627  
9p13.1-p12 
 




















Probes Genes Mean 
 
DGV 
1q21.1 146867499 147647499 8 KIAA1693,  NBPF20,NBPF16, 
CR17196, AK310441, AK311729, 
BC023516, FCGR1C, FCR1B receptor  
0.228 No 
5p14.2  23692499 24342499 7 AX747383 -0.21 No 
7q11.23 73937499 74912499 13 STAG3L2, PMS2L5, BC047594, 
BC110795, BC068610, hPMS7, 
GTF2IRD2B NCF1C, GTF2IP1, 
PMS2L14, WBSCR16, AL831977, 
DQ571357, DQ579684, LOC541473, 
TRIM73, NSUN5B,POM-121-2 
AL831977 POM121-C, SPDYE8P, 




41892499 43192499 12 BC019880, MGC21881, KGFLP2, 
AK126080, LOC554249, ANKRD20A2, 
DQ588135, AK125850, CR605783, 
AK094644, CBWD5, FOXD4L4, 
BC070322, AK128231, 
BC052332.BC071803, CCDC29, 











18427499 20377499 17 HERC2P3, DQ582260,POTEB, 
A26B1, M84131,GOLGA8E 
,DQ582025, DQ582025, DQ592322, 
OR4N4, DQ578838, M84131, 
AK058056, BC062994,OR4M2, 
AJ004954 , CR622584, AX748135, 
DQ786202, DQ599733 
0.391 No 
16p11.2 32207499 32792499 5 BC041879, DQ571479, TP53TG3, 





17p11.2 18297499 18622499 5 LGALS9C, tI132 CCDC144B, 









Probes Genes Mean 
 
DGV 
17p11.2 18752499 19077499 5 PRPSAP2, SLC5A10, FAM83G, 





41827499 42152499 6 ARL17,LRRC37A2 , ARL17P1, -0.36 No 
21q11.2 13487499 13812499 6 No genes found 0.218 No 
 





Probes Genes Mean DGV 
1p36.13 16802499 17127499 6 NBPF1 ,FLJ00313, MST1, 
AL035288, KIAA0445, MSTP9, 
BC070363, CROCC  
0.266 No 
5q13.2 69127499 70687499 18 SMA4, SERF1, SMA3, GTF2H2D, 
GTF2H2, NAIP, SERF1B, 
GUSBP1, SMN2, DQ570150, 
BC045789, 
LOC730394, AX748379, 
DQ571494, AK12386, AK31001, 
LOC730394, DQ591060, 
DQ786306, DQ575504, 
AK12386, S74729,  DQ596233, 
DQ786306, AK12386, DQ599922 
0.388 No 






71857499 75107499 48 TYWIB, SBDSP, SPDYE7P, 
POM121, WBSCR20C, NSUN5C, 
TRIM74, TRIM50, FKBP6, 
BAZ1B, BCL7B, TBL2, WBSCR14 
, MLXIPL, DNAJC30, WBSCR22, 
STX1A, ABHD11,ELN, LIMK1, 
EIF4H WBSCR5, LAT2, RFC2, 
CLIP2 ,GTF2IRD1, GTF2I, 
BC047594, BC110795, 
PMS2L14, SPDYE8P, BC68610, 
hPMS7, STAG3L1, STAG3L2, 
TRIM73, NSUN5B, BAZ1B, 
FZD9, RBAP2  
0.276 No 
7q11.23 75692499 75952499 5 FLJ37078, CCDS43604, HSPB1, 
HSP27, AX747594,YWHAG, 





99482499 100652499 18 DKfZp43L134, ZSCAN21, ZNF3, 
PP838, COP56, MCM7, 
STAG30S, AP4MI, HSMU4, 
TAF6, PVRIG, PILRB, 




X24, TFR2, ACTL6B, BAF53b, 
AK055267, GIGYF1, GNB2, 
ZAN,F LJ0009, FLJ00010, 
SLC12A9, EPHB4, TRIP6, GNB2, 








Probes Genes Mean DGV 
MUC3, TRIM56, AP1S1,VGF, 
MOGAT3, PLOD3, ZNHIT, 
UFSPI ,ZAN 
7q22.1 101822499 102082499 5 PMS2L3, PRKRIP1, ORA12, 
ALKBH4, LRWD1, KIAA0538, 
RASA4, POLR2J, BC085014, 
UPLP,POLR2J3, SPDYE2, 
RASA4, HSPC047, AK311374, 
BC085014, BC041025 
0.302 No 














































16p11.2 31492499 32532499 11 BC021555, BC000552, 
AK054698, ZNF720, FKSG41, 
ZNF267, IGHV, HERC2P4, 














Probes Genes Mean DGV 























(scaffold protein, plasma 
membrane),AK002138,CARD14(s
















17q25.3 78292499 78611061 6 FN3K (fructosamine 3 
kinase)TBCD (beta tubulin 
cofaktor),ZNF750,KIAA0988,B3G
NTL1 8(glycosyl transferase), 
0.231 No 
















Probes Genes Mean DGV 







Probes Genes Mean DGV 
 DQ580039,  DQ600587, 
DQ599874,  DQ599768, ORF416, 
LOC643837, SAMD11, HES4, 
ISG15, UNQ2998, AGRN, 
C1orf159, TNFRSF4, SDF4, 
SCNN1D, DVL1, PUSL1, TASIR3, 
UBE2J2, NOC2L, FAM132A, 
B3GALT6, KLHL17, PLEKHN1, 
CPSF3L, GLTPD1, ATAD3A-B and 




120347499 120867499 9 NOTCH2, N2 ,NOTCH2NL, 




142642499 143942499 14 NBF1, NBPF14, NBPF20, 
AF379632, AF161426, DQ786323, 
AL050141, AF379632, AF161426, 
COAS3, CR603237, PDE4DIP, 







145892499 148037499 23 KIAA1693, NBPF1, GPR89B,  
GPR89A, GPR89C, PDZK1P1, 
LOC200030, NBPF11, NBPF15, 
NBPF16, NBPF10, CR617196, 
FCGR1B, FCGR1A, AF161|426, 




4p13-12 45142499 45792499 11 GABRG1  -0.226 No 
4p15.1 29997499 30257499 5 No genes found -0.234 No 
4q13.1 63537499 63927499 5 No genes found -0.214 No 
7q11.22-
q11.23 
71597499 75042499 51 TYW1B, SBDSP, SPDYE7P, 
POM121, WBSCR20C, NSUN5C, 
TRIM74, BC073780, STAG3L2, 
LOC441259, PMS2L14, SPDYE8P, 
hPMS7, BC047594, GTF2IP1, 
TRIM50, TBL2, FKBP36, 
MLXIPLVPS370, WBSCR14, 
WBSCR22, STX1A, ELN,LIMK1, 
LAT2, RFC2, CLIP2, GTF2IRD1,T 
FII-1,STAG3L1,+++ 
0.244 No 
7q11.23 76082499 76407499 6 LOC554248, POMZP3, BC043544, 0.234 No 















18427499 19337499 9  0.64 No 
16p13.11 14982499 15372499 7 PDXDC1, LOC728138, RRN3, 








Probes Genes Mean DGV 




28437499 30127499 20 NUPR1, CCDC101, SULT1A2, 
SULT1A1, EIF3C, NPIPL1, 
AK125489, ATXN2L, SH2B1, 
RABEP2, ATP2A1, NFATC2IP, 
SPNS1, A2LG, BX647358, 
RUNDC2B, CD19, MLAS, GIYD2, 
BOLA2B, SULT1A3, KIF22,SPN, 
QPRT, TMEM219, PPX,TAOK2, 
TBX6, HIRIP3 ,MAZi, SEZgL2, 
MVP, KTCD13, FKSG86, YPEL3, 
MAPK3, ALDOA, CORO1A, 
GDPD3, IMAA, INO80E,++++++ 
0.272 No 
16p11.2 30647499 34157499 29 SRCAP, PHKG2, LOC90835, 
RNF40, ZNF629, BCL7C, CTF1, 
MYST1,ORA13, STX4, FBXL19, 
ZNF668, ITGAM, VKORC1, 
BCKDK, FUS, PYCARD, TRIM72, 




IGHV, SLC6A10P, IGH,SLC6A8, 
Z14218,+++++++ 
0,285 No 
17p11.2 18752499 19077499 5 PRPSAP2, FAM83G, BC112347, 
SLC5A10, GRAP, BC058012, 
LOC400581 
0.642 No 
17p11.2  20182499 20767499 8 CCDC144C, BC019672, 
AK310665, BC044655, LGALS9B, 








19p13.11 17062499 17452499 7 MYO9B, USHBP1 ,AIEBP, 
ANKLE1, NR2F6, C19orf62, 
OCEL1, PCIA1, DDA1 ,ABHD8, 



















In this appendix a summary table of all detected copy number variants on array numbers 
461678, 509338 and 514596 are presented. The mean values are not documented. The green 
colour for the columns marked with mean represent duplications and the red colour deletions. 
 
Summary table of all mutations found in array 461678, 509338 and 514596 
Chromosome 
number 







1 2499 787499 A02 - -  
1 32499 1722499 - - 33P  
1 120347499 120867499 - - 33P  




















1 16749999 16962499 A02 - -  
1 16769999 17159999 - 12P -  
1 16802499 17127499 - - 30P  
1 19486999 195129999 - 17P -  
2 747499 1072499 - - 25P  
3 4159999 4354999 - 8P -  
4 29997499 30257499 - - 33P  
4 45142499 45792499 - - 33P  
4 58304999 64024999 - 4P -  
4 63537499 63927499 - - 33P  
4 98549999 98762499 A01 - -  
4 131337499 131449999 A02 - -  
5 178619999 178814999 - 20P -  
5 23692499 24342499 - - 26P  














6 168089999 168284999 - 8P -  
6 
 
57557499 58402499 - - 23P  
7 487499 877499 - - 30P  
7 62302499 62757499 - - 23P  
7 71629999 76439999 - 4P -  













7 71662499 72442499 - - 23P  




























7 74812499 74937499 A01 - -  
7 74327499 74847499 - - 12(1)  
7 75692499 75952499 - - 30P  
7 76082499 76407499 - - 33P  
7 99482499 100652499 - - 30P  
7 99662499 99762499 A02 -   







-   







-   
8 48717499 48977499 - - 12p (1)  





- 7P  
4P 
 
8 7214999 7864999 - 10P   
8 143552499 144137499 - - 24P  
9 12122499 12512499 - - 33P  
9 25609999 25869999 - 8P -  
9 31274999 31349999 A02 - -  
9 38999999 41859999 - 7P -  
9 38967499 70167499 - - 33P  







- - 25P 
30P 
 




























- - 23P 
25P 
 
9 42867499 43712499 - - 23P  
9 43224999 67339999 - 7P -  


















- - 9P, 24P  
9 65454999 65779999 - 12P -  
9 65747499 70167499 - - 30P  













10 46149999 46799999 - 12P -  





- 9P  
9P 
 












13 62009999 62594999 - 10P -  
14 18427499 19337499 - - 33P  













































- - 12P(1) 
12P(2) 
 

















15 32499999 32694999 - 7P -  
16 14982499 15372499 -  33P  
16 16152499 16672499 -  23P  
16 22359999 22554999 - 17P -  





- - 23P 
33P 
 



























- 2P  
26P 
 
17 20182499 20767499 - - 33P  




















- - 26P 
26P,33P 
 
17 73027499 74002499 - - 30P  
17 75432499 75952499 - - 30P  
17 76602499 77837499 - - 30P  
17 78292499 78611061 - - 30P  





- - 33P 
33P 
 
19 184227499 18687499 - - 33P  












20 62172499 62410787 - - 30P  












- - 23P,26P,33P, 
30P 
 




















- -  







- -  























Documentation of the laeverin gene sequence. Forward primers (blue) and reverse primers 
(pink) used in sequencing analysis are shown. 





cgtggggtctgtctcttcgaacccaaaggggtacgcgtctgggtgagccaggtccgcctc Primer 1_1F 
...........................  




CTGCGAGCGCGTCCCACCGTCGGAGCTGCCTGGACTCAGGGACTTGGAAGCCGAGTCTTC Primer 1_2F 










gcgggtccagctgactaccgtgtccaggtgcgcgtctgctgccctttccaaagaatcccc Primer 1_2R 
............................................................ 
gaattctaaggtgccatgataattggagtgtgttggtgtgatgggatgggcagtgaggaa 
gatgagaggaaatttcctctaacacaccaggctaacttacaagccatcatctctcaatgt Primer 2F 
ttttttattccactgggttgaaataaaaataaataaaaatttccccaaaatgtatttcag 
GGCCCTGTTAGCGTCCCAGCTGGAACCAACATTTGCCAGGTATGTTTTCCCTTGTTTTGA 
TGAGCCAGCTCTGAAGGCAACTTTTAATATTACAATGATTCATCATCCAAGTTATGTGGC Exon 2 
CCTTTCCAACATGCCAAAGCTAG 
gtaagtaatgctttctgtctatatctagctgtctatctatataagctttgtaatcacatt 
tataccagtagcttttctaggcagtgtattatggtgtattataattacagtctactataa Primer 2R 
............................................................ 
gctagactatgaggaatagctggaaaggagtagctgggtgacaattgacttgacaaatta Primer 3F 
tttcaaagacatgtaattgcttagatttgctgtgatttgaactaaaataaaattctctag 




tctttctgcatccagtggttatggctgcatatccccaaatcgcttcctagttctctctcc Primer 3R 
............................................................  
acttagtgaacagccttcaggggttttctcaggacatgtaagcatgcaagcattttatta 
tgcagcttcttctggaaaggtaagactttggttcagcagcagggaattggagcaagcaga Primer 4F 
ctacctctttccaaaatcactactggttttcctaatcactgcttaactgttttgatttag 
ATACGCATCTGGGCCCGGAAAGATGCAATTGCAAATGGAAGTGCAGACTTTGCTTTGAAC 
ATCACAGGTCCCATCTTCTCTTTTCTGGAGGATTTGTTTAATATCAGTTACTCTCTTCCA Exon 4 
AAAACAG 
gtgaggtaatcttttcctttcagtgcatttggtttcctgttatttgggcccttggttgag Primer 4R 
............................................................  










caaagtatgacagtgagtaaaaatggggaagactcagattcagggtggatttgagctact Primer 5R 
............................................................  
gatggcaaataaattttaattatgtcttttgaccttacatttacttaacatgcaattaca Primer 6F 
acgaatataacttaaaaattaaatttaagaaagctctttttttcttctcatttccaaaag 




ccaaaaataatttgtgttagctttttgatatttttttttaattccaggctttttatctat Primer 6R 
............................................................  












tgcaaaatgcaatcaggagcacagctcagaatattgcttataaatatggaatgtgtcagt Primer 8_9F 
atgtggatattgaattttgttcaaataatggacagcttcttttgtcctag 




TCATATTTGAAGACATTTTCCTACTCAAACGCTGAGCAAGATGATCTATGGAGGCATTTT Exon 9 
CAAATG 
gtaattgtcctactttctgacacattcttgctgagttgttttgtatgatacaggaaaaga 
ctgggaggccatgggtgaatggcagttccacaggaaaacagctttgtcttgttgtagaac Primer 8_9R 
............................................................  
ctacataagtgaggaagagaatagctaccgagtttctttttggagattgctacttcaaaa Primer 10F 
tgtttcacggataaccttacctgcctttgtggtgattttttaaaacag 
GCCATAGATGACCAGAGTACAGTTATTTTGCCAGCAACAATAAAAAACATAATGGACAGT 
TGGACACACCAGAGTGGTTTTCCAGTGATCACTTTAAATGTGTCTACTGGCGTCATGAAA Exon 10 
CAGGAGCCATTTTATCTTGAAAACATTAAAAATCGGACTCTTCTAACCAGCAA 
gtaggtagctttgctcctctttgtcttcaccttccttggggttgagctctgacccaatgg 
aatccagcctgtgggtgaagaagcgttacccccgctgggcatacacacttctgcaatgtg Primer 10R  
............................................................ 
agagagaatgaccaaagaaactgagttctgtgtgctatttcatcatctctttaatagtgg Primer 11F/11F1 
ctcagagtgtatgtttttatgtgtgaaaagtaactaatttttttattttcttccaataag 
TGACACATGGATTGTCCCTATTCTTTGGATAAAAAATGGAACTACACAACCTTTAGTCTG Exon 11 
GCTAGATCAAAGCAGCA 
gtaagtaacaaattttaaaaacatctttatatatatgcatatgtaaaggcagggaataaa 






ATATGACTGGATATTATAGAGTTAATTATGATAAATTAGGTTGGAAGAAACTAAATCAAC Exon 12 
AACTTGAAAAGGATCCTAAG 
gtaaggttacttttgatacttttaattaaatataatttataatgccttctctagtgtttt 
agaagttgaacattctggtgggaagagattccaccttcattcccgcccctcacctccagg Primer 12R2 
catgcaaaagatttttttttcttattcttaacaagtggagattttgattaaatgtgttgt 














agataagtcacgtgaaggtgctttataggcagcagtaatctttaaattgttgttattttg Primer 13F 
aaaactttgcggaaaaatgttctcatcttcttctgggcatatttgggtctaattctgcag 
GCGATTCCTGTTATTCACAGACTGCAGTTGATTGATGATGCCTTTTCCTTGTCTAA Exon 13 
gtgagtatattttcttctctcatggtttcagaatataccttgagacctttataaaaataa 
tagcttcatcactatgaatttgattatttagtctatacaggccataactgattaagatta Primer 13R 
............................................................  
cttgacttattcacatgccttattgaagtcatgcattgaaacatggaacaaatatcgaac Primer 14F 
gtatgcaaattacttagcaagtgaaggttttttgagtgtgtgtgtttttaaatcaaacag 
AAACAATTATATTGAGATTGAAACAGCACTTGAGTTAACCAAGTACCTTGCTGAAGAAGA 
TGAAATTATAGTATGGCATACAGTCTTGGTAAACTTGGTAACCAGGGATCTTGTTTCTGA Exon 14 
GGTGAACATCTATGATATATACTCATTATTAAAG 
gtaatttcattctttcttatgtagtttttaaataaatcctctcttcttcttttcatattt 
tagccagcatctgtgagacaggtcttttccaaagtaatagtcttagttccatatatatat Primer 14R 
atatatatatatggaagtatatacatttccttaacaagggctgattgatcttagaagaaa 
............................................................  
ttctgaagaaatatctgccacttgtctatcaatgtcttttcagataaataaatagaaaca Primer 15F 
cagtgaaaattcagtgtttgcaagccagaactaacagtgtattttctttattgtttatag 
AGGTACCTATTAAAGAGACTTAATTTAATATGGAATATTTATTCAACTATAATTCGTGAA 
AATGTGTTGGCATTACAAGATGACTACTTAGCTCT     Exon 15 
gtaagtatgttttcagaagtgataattgaataaaatgcattcatattaataggcttccag 
aagtaataaaataaaatcttcatatctgttattcattgagagattttatatgctattatt Primer 15R 
............................................................  
gatgtcattgaaaggatatttaaaaatacccatctttttatgaaacacatattcttggag Primer 16F 
gcagagaaaatgaaggtggtaatgcaaaataaactgtttttctttgactttttcttcaag 
AATATCACTGGAAAAACTTTTTGTAACTGCGTGTTGGTTGGGCCTTGAAGACTGCCTTCA 
GCTGTCAAAAGAACTTTTCGCAAAATGGGTGGATCATCCAGAAAATGA   Exon 16 
gtaagagtaatatcataattcctcttgtttttgtcctattttagcaccagcaatttccct 
ttttgatgtactcactgtgggaatgagtgttttgctttcacttggttaggcgctctctcc Primer 16R 
............................................................ 




AGAGTGGGACATCTTGTTAAATACTTACACTAATACAACAAACAAAGAAGAAAAGATTCA Exon 17 
ACTTGCTTATGCAATGAGCTGCAGCAAAGACCCATGGATACTTAACAG 
gtgattatggtcaacttaccttgaaagtttctgttataggaattaaattaataaaggaaa 
aaaaatagaaatgtgctaatgtaagtattaaaacgttgcgtatttgtgcttcactacctt Primer 17R 
agaaccatgggattttgattttgtttatttaaattaactctttatgttggatgtttaaaa Primer 18F 
tgtattttttgaaaatgcacttttgcag 
ATATATGGAGTATGCCATCAGCACATCTCCATTCACTTCTAATGAAACAAATATAATTGA 
GGTTGTGGCTTCATCTGAAGTTGGCCGGTATGTCGCAAAAGACTTCTTAGTCAACAACTG Exon 18 
GCAAGCTGTGAGTAAAAG 
gtaagaaggaaagtgagacctttctttcatttaggccactggtttggcactggaagctca Primer 18R 
gctttagtctagcttggaagctcagctttagtctagctaggccacaaacgtcctttgcat 
............................................................ 
ttagatttgtgacataggaattaataggggccatacacttgaccttcatctgctatataa Primer 19F 
aatatagctttattttgcaaaatgctttccacccttgattaacatcttattgccttgtag 





acctgttcatggagggtggcacttcatcctctctcacctgaatgcaggggactctggccc Primer 19R 
agggttcccgtcccagaccgggcttccctccatcccacctttgccatcactgccagtcat 
............................................................ 










GTCACTTCATGTTGGGTTATAATCCCACAGAATTTACTTTAAATGTCACGTAAAAACAAA Primer 20_2F 
TTCACCTAAGATAGTCTTGCTTATTTTGTTGCGAAGGCCAGTGGAATATAAAAATCAATG 







AGTGGGATGGACACCCTTTCAGCCTAAGCGTACGAGTGAAAACAATGATGTCAAAAGACA Primer 20_3F 






GGAGTATGACATCAATTAACAGTCTTTAAAGATGTTACATACGCTCAAAGCAATGTGATT Primer 20_4F 
AAGACTTTTTGCCTATTTCTTGTATAAGTTAAGGCAGCCATAAATGAAAATACAAAACAA 




caaagtgttgtagctgagataccttcctgttttttttcttaaacactcattctatatttc 3’Downstream seq. 
ccatatttcctctgataatgaatctcatctttcaataactttgtcttcacttgtcctctc 
aactgcttttctcttcctcttcttcttctgtgtcttagtccattttgtgctgctgtcata Primer 20_4R 
gaataccttagactgggtaatttatgaagaacagagatgagtttcttaccattctgaagg 
ctggagattc.................................................. 
 
 
 
